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1.1 Anatomy of the eye
1.1.1 Visual pathway
Vision is arguably the most used of the five senses and is one of the primary means 
that we use to gather information from our surroundings. When we look at an 
object, visible light waves reflected by that object enter the eye through the cornea 
to finally be absorbed by the photoreceptors of the retina (Figure 1.1). The retina 
is the light-sensitive tissue lining the inner surface of the eye. One could argue that 
vision starts here when the photoreceptors convert light into electrical impulses, 
which are signaled to the brain via the optic nerve. 
Figure 1.1. Anatomy of the human eye
1.1.2 Retina
Anatomy
During embryonic development, the retina and the optic nerve originate as 
outgrowths of the developing brain. The retina is a thin transparent membrane with 
an area of about 266 mm2 and is the only part of the central nervous system that can 
be visualized non-invasively.
Histologically, the retina has several distinct layers of neurons interconnected by 
synapses and supporting cells (Figure 1.2). The deepest retinal layer is the retinal 
pigment epithelium (RPE). This layer as well as the retinal vascular endothelium 
possess a well-developed junctional complex that includes both adherence and 
tight junctions, called the blood-retina barrier. The physiological function of the RPE 
layer is multifaceted. Besides the active transport of nutrients and growth factors 
by controlling solute and fluid permeability between the choroidal vessels and 
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subretinal space, the RPE layer also plays a key role in the conversion and storage 
of retinoids, the phagocytosis of shed photoreceptor outer segment tips, and the 
absorption of scattered light.1
The remaining nine layers compose the neurosensory retina. This part of the retina is 
responsible for converting light into electrical impulses, initial neuronal processing, 
and subsequently transmission to the optic nerve. The order of the layers from the 
outer to inner neuroretina are 2) the photoreceptor layer, containing the outer and 
inner segments of the rods and cones, 3) the external limiting membrane, composed 
of the closely apposed processes of Müller cells from the fifth layer, 4) the outer nuclear 
layer, containing the cell bodies of the photoreceptor cells, 5) the outer plexiform 
layer, the zone of synapses between the interneurons and the photoreceptors, 6) the 
inner nuclear layer, composed of the cell bodies of the interneurons and Müller cells, 
7) the inner plexiform layer, the zone of synapses between the interneurons and the 
ganglion cells, 8) the ganglion cell layer, containing the cell bodies of the ganglion 
cells, 9) the nerve fiber layer, composed of the unmyelated axons of the ganglion 
cells that course towards the optic disc, and 10) the internal limiting membrane, 
like the external limiting membrane formed by the apposed processes of the same 
Müller cells. This layered pattern is similar across the entire human retina, with the 
fovea (see below) as the only exception.
Macula lutea
The central area of the posterior retina is defined as the macula lutea, or yellow 
spot (Figure 1.3). The conventional boundary of the macula lutea, as defined 
histologically, is the area that contains two or more layers of ganglion cells, spans 5 to 
6 mm in diameter, and is centered vertically between the temporal vascular arcades. 
Figure 1.2. Schematic representation of 
the cells and layers of the human central 
retina. 1: retinal pigment epithelium; 2: 
layer of rods and cones; 3: external limiting 
membrane; 4: outer nuclear layer; 5: outer 
plexiform layer; 6: inner nuclear layer; 7: 
inner plexiform layer; 8: ganglion cell layer; 
9: nerve fiber layer; 10: internal limiting 
membrane.
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Figure 1.3. The position of the macula lutea, fovea centralis and 
foveola in the posterior retina. (A) Color fundus photograph 
with ETDRS grid chart to define subfields of the macula. (B) 
Cross-sectional presentation of the retina with the anatomical 
differences between the different subfields of the macula .
The yellow color is attributed to macular pigment, consisting of the xanthophyll 
carotenoids lutein, zeaxanthin and meso-Z, which are powerful antioxidants and 
act as a filter of actinic short-wavelength blue light, thus limiting (photo-) oxidative 
damage to retinal cells.2-5
The central 1.5 mm of the macula lutea is called the fovea centralis (or fovea), which 
is anatomically characterized by a depression in the inner retinal surface. Its floor in 
the very center is called the foveola, an area of 0.35 mm in diameter. The fovea is 
dominated by cone photoreceptors, which are concentrated at maximum density 
(~199,000/mm2) in the foveola, in the absence of rod photoreceptors. Moreover, 
retinal capillaries are absent and the axons of the photoreceptors almost immediately 
bend away from the photoreceptor bodies, nearly parallel to the retinal surface, 
thereby minimizing light scatter. It is this anatomy and photoreceptor composition 
that makes the fovea specialized for high spatial acuity and color vision. Although the 
fovea comprises only 0.5% of the retina, approximately 50% of the nerve fibers in the 
optic nerve carry information from the fovea, due to its dense cone photoreceptor 
concentration. 
Photoreceptors
Light striking the retina must travel through the full thickness of the human retina 
to reach the rods and cones. These photoreceptors convert light into electrical 
impulses by means of the phototransduction cascade.6,7 The density and distribution 
of the rod and cone photoreceptor cells vary with topographic location within the 
retina (Figure 1.4). The fovea contains a densely packed arrangement of cone 
photoreceptors with a peak density of about 199.000 cones/mm2. The number 
of cone photoreceptors falls steeply with increasing eccentricity away from the 
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foveal center; the periphery contains a minimum of cone photoreceptors. The rod 
photoreceptors have their greatest density in a zone lying about 20° from the foveal 
center, where they reach a peak density of about 160.000 rods/mm2.8,9 Although the 
rod photoreceptor density is high, the visual acuity in this region is limited because 
of summation of multiple rod photoreceptor responses in each receptive field. This 
offers sensitivity at the cost of image resolution. The density of rod photoreceptors 
decreases towards the periphery.
The rod photoreceptors contain the visual pigment rhodopsin and are sensitive 
to blue-green light with a peak sensitivity around 500 nm wavelength of light. In 
contrast to cones, rod photoreceptors are sensitive enough to respond to a single 
photon of light, thus enabling vision in dim light (scotopic vision). Rods are essential 
for detection of contrast, brightness, as well as motion. Cone photoreceptors, on 
the other hand, contain cone opsins as visual pigment and, depending on the exact 
structure of the opsin molecule, are sensitive to either long wavelengths of light 
(L-cones), medium wavelengths of light (M-cones) or short wavelengths of light 
(S-cones). L-cones are known to be maximally sensitive to wavelengths peaking at 
564 nm (red light), M-cones at 533 nm (green light) and S-cones at 437 nm (blue light), 
respectively. The cone photoreceptors function at bright light (photopic vision) and 
because of their ability to detect different wavelengths of light are essential for color 
vision and high spatial acuity.
Apart from the capture of light in the rod and cone photoreceptors, a subset of 
ganglion cells is also photosensitive, expressing an opsin-like protein called 
melanopsin.10 These ganglion cells mediate non-image forming visual responses. As 
such, they play a key role in the rapid adjustment of pupil size, in light modulation of 
activity, and in the adaptation and fine tuning of the circadian clock to environmental 
light. These non-image forming, adaptive ocular photoresponses are thus important 
in circadian rhythm entrainment.
Figure 1.4. Density distributions of cones and rods with respect to the angle relative to the foveal 
center along the horizontal meridian.
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1.1.3 Bruch’s membrane
Bruch’s membrane is an unique pentalaminar structure, which acts as a semi-
permeable filter for the reciprocal exchange of biomolecules between the retina and 
the choroid. Starting with the innermost layer, the five layers of Bruch’s membrane 
are 1) the basement membrane of the RPE, 2) the inner loose collagenous layer, 3) 
the middle layer of elastic fibers, 4) the outer loose collagenous layer, and 5) the 
basement membrane of the endothelium of the choriocapillaris. The thickness of 
Bruch’s membrane increases with age and almost doubles in size during life.11,12 The 
principal part of Bruch’s membrane thickening occurs in the inner loose collagenous 
layer, followed by the outer loose collagenous layer. This process starts in the retinal 
periphery, where RPE gene expression of most structural components of Bruch’s 
membrane appears to be higher than in the macular area.13,14 
In general, the thickening of Bruch’s membrane is caused by increased deposition and 
cross-linking of (less soluble) collagen fibers and increased deposition of lipids and 
other substances such as complement components.12,15-20 This thickening eventually 
disturbs Bruch’s membrane integrity and causes a sharp reduction in trans-RPE fluid 
and nutrient transport, especially in the macula, where Bruch’s membrane appears 
to be thinnest.12,21-23 The potential correlation with neovascular ingrowth agrees 
well with the notion that thickening of Bruch’s membrane renders the membrane 
more brittle and more susceptible to breaks, allowing for neovascularization as 
some sort of tissue repair mechanism.24 Subretinal deposits, such as basal laminar 
deposits, basal linear deposits and drusen – the precursors of age-related macular 
degeneration (AMD) – preferentially develop between the basement membrane of 
the RPE and the inner loose collagenous layer of Bruch’s membrane.21,22,25,26 Although 
it is currently insufficiently understood why drusen develop mainly in the macular 
area, a combination of specific structural, molecular and functional properties 
predispose the macula to develop drusen. First, the high metabolism associated 
with the extremely high density of photoreceptors, particularly in the perifoveal ring, 
may contribute to drusen formation. Local phagocytosis of photoreceptor outer 
segments by the RPE causes a highly focused and localized peak of oxidative stress, 
and focal build up of membranous waste products. Secondly, significant differences 
in functional RPE properties, as annotated by differential gene expression profiles, 
may play a role.14 Third and last, the thinner and more open maze of the elastic layer 
of Bruch’s membrane compared to the periphery may predispose the macula to 
drusen formation. Most likely, oxidized molecules may get physically or chemically 
trapped easier, thereby triggering the first events of drusen formation in the macular 
area.27
1.1.4 Choroid
The choroid, also known as the choroidea, is the vascular layer of the eye positioned 
between Bruch’s membrane and the sclera. The choroidal blood flow is the highest 
rate of all body tissues and supplies oxygen and nourishment to the RPE and the 
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outer retina.28 More than 90% of the oxygen provided by the choroid is consumed 
by the photoreceptors.29 A second function of the choroidal blood flow is to protect 
the retina from heat generated during exposure to bright lights by acting as a heat 
sink for exogenous thermal radiation.28,30-32 In addition to its vascular functions, the 
choroid contains secretory cells, involved in modulation of vascularization and in 
growth of the sclera.33-37
Histologically, the choroid can be dissected in four layers. Starting from the Bruch’s 
membrane side, these are 1) the choriocapillaris, 2) Haller’s vascular layer, 3) Sattler’s 
vascular layer, and 4) the suprachoroidea.38 The human choroid has a maximal 
thickness (220 µm) in the central region, while it progressively narrows to 10 µm 
in the periphery. In the posterior pole, the choriocapillaris consists of a mosaic of 
vascular lobes (Figure 1.5). Towards the periphery, the capillary arrangement of the 
choriocapillaris becomes more ladder-like, with the choriocapillaris connecting the 
arterioles and venules at right angles. This difference in vascular architecture may 
largely explain the increased blood flow in the macula, a result of the more efficient 
lobular pattern in this area. With age, the thickness of the choriocapillaris and the 
capillary lumen diameters decrease.11 It is this degeneration of the choriocapillaris 
that seems to play a role in the pathogenesis of AMD.39
1.2 Clinical evaluation of retinal anatomy and function
The clinical evaluation of the retina requires a combination of conventional 
examinations and more recently developed specialized imaging techniques. Results 
of visual acuity measurements indicate the degree of foveal involvement and are 
important to determine disease progression in follow-up examinations. Evaluating 
the aspect of the retina is essential to get more information about the nature of 
the disease. This section provides an overview of the most frequently used imaging 
techniques in the clinical characterization of AMD, the topic of this thesis.
Figure 1.5. Schematic representation of the anatomic variation in the angioarchitecture of the 
choriocapillaris at the different topographical sites. (A) Lobular pattern of the posterior choriocapillaris. 
(B) Spindle pattern of equatorial choriocapillaris. (C) Ladder pattern of peripheral choriocapillaris. A, 
arterioles; V, venules.
A CB
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1.2.1 Ophthalmoscopy
The simplest examination technique is direct ophthalmoscopy, which provides a 
monocular, high-magnification (15x) image of the retina. However, the instrument’s 
lack of stereopsis, small field of view, and poor view of the retinal periphery limits its 
use. These shortcomings are overcome by using a monocular or binocular indirect 
ophthalmoscope in combination with a (20, 28 or 30 diopter) handheld lens that 
dramatically increases the field of view with lower magnification (2-3x). To evaluate 
subtle retinal changes, slit-lamp biomicroscopy is preferred. A wide variety of 
(contact) lenses are used for viewing the retina with the slit lamp, all with their own 
specific advantages. For better comparison of follow-up examinations, color fundus 
photographs may be taken at regular intervals.
1.2.2 Fluorescein angiography
Fluorescein angiography (FA) is a technique for examining the circulation of 
the retina and choroid using the dye tracing method. After the administration of 
intravenous or oral sodium fluorescein, which under normal circumstances does 
not pass the blood-retina barriers of the RPE and retinal vessels, an angiogram is 
obtained by photographing fluorescence emitted by the dye after illumination with 
blue light at a wavelength of 490 nanometers. Lesions on FA show variable degrees 
of hyperfluorescence or hypofluorescence, depending on the nature and site of the 
lesion relative to the normal anatomical structures. FA can also aid the detection 
of a particular subtype of drusen called cuticular drusen, which typically appear as 
“stars-in-the-sky”.
1.2.3 Optical coherence tomography
Optical coherence tomography (OCT) is a noninvasive, noncontact imaging 
technique that provides real-time images of the retina in micrometer-resolution. This 
high resolution is achieved through the principle of low-coherence interferometry, 
which is based on measurements of reflected or backscattered light of different 
internal tissue microstructures in a way that is analogous to ultrasonic pulse-echo 
imaging. From the resulting measurements, one can derive the reflectivity profile 
along the beam axis. This one-dimensional depth scan is called the A-scan. The OCT 
scan performs many adjacent A-scans in order to create two- or three-dimensional 
images of the retina. In Chapter 5 of this thesis, we demonstrate the potential of this 
imaging modality by evaluating the short-term changes of cuticular drusen.
1.2.4 Scanning laser ophthalmoscopy
The confocal scanning laser ophthalmoscope (cSLO) provides retinal images by 
using a laser beam with a specific wavelength that rapidly scans the retina in a 
raster fashion. The reflected light is detected by a confocal photodetector that is 
conjugate to the retinal plane, and the digitized signal can either be recorded on 
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videotape or fed to a frame-grabber interfaced to a computer. The possibility to 
image with several different wavelengths offers the possibility to produce retinal 
images with or without dyes such as fluorescein or indocyanine green, and permits 
selective examination of different tissue depths. By this means, cSLO is capable of 
imaging retinal structures poorly seen by ordinary fundus cameras and does so using 
low levels of light exposure and improved contrast.
1.3 Introduction to molecular genetics
It has been known for centuries that certain diseases, including a wide variety of 
retinal disorders, run in families. In order to understand how, at the molecular 
level, such a diversity may arise and why some diseases run in the family, a basic 
knowledge of heredity is required. This section provides an overview of the structure 
and function of deoxyribonucleic acid (DNA) and a basic knowledge of the structural 
alterations that may occur.
1.3.1 DNA structure and function
DNA is an information macromolecule containing the genetic instructions used in the 
development and functioning of all known living organisms. These DNA molecules 
consist of two long polymers of four different repeating chemical bases (adenine, 
A; thymine, T; guanine, G; and cytosine, C) with a linear backbone composed of a 
5-carbon sugar to which are attached one or more phosphate groups (Figure 1.6). 
A sugar with an attached base and phosphate group therefore constitutes the basic 
repeat unit of a DNA strand, a nucleotide.
The DNA’s genetic information is encoded by the linear sequence of nucleotides in 
its strands. Regions that spell out the exact instructions required to create a particular 
protein are called the genes. In humans, the DNA encodes approximately 20.000 to 
25.000 genes. Genes contain an open reading frame that can be transcribed into a 
protein, as well as regulatory sequences such as promoters and enhancers, which 
control the transcription of the open reading frame. Only about 1.5% of the human 
DNA consists of protein-coding genes. However, DNA sequences that do not code 
proteins may still encode functional molecules, which are involved in the regulation 
of gene expression.40-44 
During the process of transcription, the information stored in a gene’s DNA is 
transferred to a similar molecule called ribonucleic acid (RNA) in the cell nucleus. 
Both RNA and DNA are made up of a chain of nucleotides, but they have slightly 
different chemical properties. The type of RNA that contains the information 
for making a protein is called messenger RNA (mRNA) because it carries the 
information, or message, from the DNA out of the nucleus into the cell’s cytoplasm. 
The second step in translating the genetic code of a gene into a protein, takes 
place in the cytoplasm. The mRNA interacts with a specialized complex called a 
ribosome, which “reads” the sequence of the mRNA nucleotides. Each sequence of 
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Figure 1.6. Schematic representation of the DNA structure. DNA is made of four types of nucleotides, 
which are linked covalently into a polynucleotide chain (a DNA strand) with a sugar-phosphate 
backbone from which the bases (A, C, G, and T) extend. A DNA molecule is composed of two DNA 
strands held together by hydrogen bonds between the paired nucleotides. The arrowheads at the ends 
of the DNA strands indicate the polarities of the two strands, which run anti-parallel to each other in the 
DNA molecule. In the diagram at the bottom left of the figure, the DNA molecule is shown straightened 
out; in reality, it is twisted into a double helix, as shown on the right.
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three nucleotides, called a codon, usually codes for one particular amino acid. These 
amino acids are the building blocks of proteins. A type of RNA called transfer RNA 
(tRNA) assembles the protein, one amino acid at a time. Protein assembly continues 
until the ribosome encounters a “stop” codon, a sequence of three nucleotides 
(TAG, TAA, and TGA) that does not code for an amino acid, but terminates the 
process of translation instead.
1.3.2 Mutations, single nucleotide polymorphisms, and pathogenicity
Human DNA is not a static entity. Instead, it is subject to a variety of different types 
of heritable change. Large-scale abnormalities involve loss or gain of large parts of 
DNA (chromosomes). These chromosomal abnormalities can cause different types of 
syndromes, like Down syndrome (which is caused by three copies of chromosome 21, 
rather than two). Smaller scale abnormalities, which most often have smaller effects, 
can be categorized into two different classes: Single nucleotide polymorphisms 
(SNPs) and mutations.
Single nucleotide polymorphisms
SNPs are DNA sequence variations that occur when a single nucleotide is altered. 
An example of a SNP is the alteration of the DNA sequence ACG GTT AGT to ACG 
TTT AGT, where the second “G” is replaced by a “T”. For such a variation to be 
considered a SNP it must occur in at least 1% of the population. On average, SNPs 
occur every 250 to 300 nucleotides along the 3-billion-nucleotide human DNA, 
contributing to about 90% of all human genetic variation.45 Since only 1.5% of the 
human DNA consists of protein-coding exons, most SNPs are found between these 
coding regions. When SNPs occur within a protein-coding part of a gene or in a 
regulatory region near a gene, they may play a role in disease by affecting the gene’s 
function or expression.
Although individual SNPs do not usually cause disease, many SNPs have proven 
to be associated with an individual’s response to certain drugs, susceptibility to 
environmental factors such as toxins, and risk of developing particular diseases like 
AMD (Chapter 2). By this means, genetic association studies of SNPs can lead to the 
first insights into the pathophysiology of a disease.
Mutations
Mutations are rare (occuring in <1% of the population) alterations in the DNA 
sequence that usually have a large effect on the protein that is encoded by the 
mutated gene. According to the specific molecular changes at the DNA level, 
mutations can be classified as: 1) single nucleotide substitutions, 2) insertions, or 
3) deletions. A single nucleotide substitution is, similar to a SNP, the replacement 
of a single nucleotide by another. An insertion involves the addition of one or more 
nucleotides. If an insertion occurs in a coding sequence and involves one, two or 
more nucleotides which are not a multiple of three (the sequence unit that encodes 
an amino acid), it will disrupt the reading frame. A deletion involves the loss of one 
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or more nucleotides. Again, if it occurs in coding sequences and involves one, two or 
more nucleotides which are not a multiple of three, it will disrupt the reading frame.
Based on their structural effects, mutations can be classified into synonymous 
and non-synonymous variations. The first is a DNA sequence alteration that does 
not alter the amino acid sequence of the gene. The second, a non-synonymous 
mutation, leads to an alteration in the encoded protein and can occur in one of the 
following ways: 1) missense, 2) nonsense, or 3) frameshift (Figure 1.7). When a single 
nucleotide substitution results in coding a different amino acid and the synthesis 
of an altered protein, it is termed missense mutation. If the substitution leads to 
the generation of one of the stop codons (TAG, TAA, and TGA), which results in 
premature termination of the protein, it is termed nonsense mutation. If a mutation 
involves a deletion or insertion of nucleotides which are not a multiple of three, it 
will disrupt the reading frame what is known as a frameshift mutation. The amino 
acids downstream of the mutation bear no resemblance to the normal sequence 
and will most likely seriously affect protein function. In addition, it is not unusual for 
a frameshift mutation to also result in a stop codon downstream of the mutation.
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Fig. 1.7. Types of gene 
mutations. (A) Original 
DNA sequence for an 
amino acid sequence. 
(B) Missense mutation; 
the nucleotide “G” 
is replaced by “A” in 
the DNA sequence, 
introducing an incorrect 
amino acid in the protein 
sequence. (C) Nonsense 
mutation; the nucleotide 
“C” is replaced by “T” 
in the DNA sequence, 
signaling the cell to 
shorten the protein. (D) 
Frameshift mutation; one 
nucleotide (“A”) is added 
in the DNA sequence, 
changing the amino acid 
sequence that follows.
A
B
D
C
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Apart from the mutations in coding DNA, mutations in non-coding DNA would not 
be expected to have an effect on protein function/expression unless they occur in 
the DNA sequences involved in gene regulation. Mutations in regulatory elements 
can affect the level of gene expression, while mutations in splice junctions can result 
in coding sequences being removed from, or non-coding sequences being added 
to, the mRNA molecule.
1.4 Age-related macular degeneration
Age-related macular degeneration (AMD) is the most common cause of visual 
impairment and blindness among the elderly in industrialized nations, affecting 
worldwide 30 to 50 million individuals.46-51 This retinal disease, characterized by a loss 
of central, color and sharp vision due to a progressive deterioration of the macula, 
has a tremendous impact on the ability of patients to perform critical activities of 
daily living such as reading and driving (Figure 1.8). As such, the impact of AMD on 
the independence and well-being of those affected can be devastating.52 
1.4.1 Early age-related macular degeneration and drusen
Early AMD is present when a spectrum of changes is observed in the ageing 
macula before the onset of overt loss of vision.53 Among these changes, drusen 
are considered as the most characteristic and earliest physical signs of AMD.54,55 
Drusen usually appear after the age of 50 years and are seen on ophthalmoscopy 
as focal subretinal deposits ranging in color from white to yellow, sometimes 
with a crystalline glittering aspect. At histological examination, drusen consist of 
amorphous extracellular material lying between the inner collagenous zone of 
Bruch’s membrane and the basal lamina of the RPE.22,25,56 Although their exact origin 
remains unproven, a profile of the molecular composition of drusen indicates that 
they are the result of a chronic inflammatory stimulus that exacerbates the effect of 
A B
Fig. 1.8. Visual distortion by age-related macular degeneration (AMD). (A) Normal vision. (B) The same 
scene as viewed by a person suffering from advanced AMD.
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Fig. 1.9. Drusen phenotypes in age-related macular degeneration. Color fundus photographs (1A, 
2A, 3A, 4A, 5A), fluorescein angiographs (1B, 2B, 3B, 4B, 5B), and optical coherence tomographs (1C, 
2C, 3C, 4C, 5C) of several eyes showing hard drusen, soft drusen, crystalline drusen, reticular drusen 
or cuticular drusen. Hard drusen are visible as small yellow pinpoint lesions (1A; white arrowheads) 
with corresponding hyperfluorescent spots in the fluorescein angiogram (1B). A representive OCT scan 
shows the dome-shaped deposition of material under the retinal pigment epithelium (RPE) (1C). Soft 
drusen are identical to hard drusen though they are typically larger (2A, 2B, 2C). A crystalline druse is 
visible as a glistening, bright yellow lesion (3A; white arrowhead) with a corresponding hyperfluorescent 
spot in the fluorescein angiograph (3B). The OCT scan shows the development of RPE atrophy in the 
area corresponding to the crystalline druse (3C). Reticular drusen are visible as grayish spots (4A) with 
corresponding hypofluorescent lesions in the fluorescein angiogram (4B). The OCT shows relatively 
flat aggregates between the boundary of the inner and outer segments and the underlying RPE (4C). 
Cuticular drusen are visible as numerous hard drusen scattered through the fundus (5A). Fluorescein 
angiography reveals the pathognomic “stars-in-the-sky” appearance (5B). The OCT scan shows multiple 
small RPE elevations (5C).
1A 1B 1C
2A 2B 2C
3A 3B 3C
4A 4B 4C
5A 5B 5C
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primary pathogenic stimuli, which are believed to be cellular remnants and debris 
derived from degenerated RPE cells.57 
Various drusen classification systems have been described, reviewed and/or 
proposed by a number of investigators in an attempt to estimate the contribution 
of different drusen phenotypes to the development of advanced AMD.53,58-60 The 
terminology most commonly used to distinguish drusen phenotypes are “hard”, 
“soft”, “crystalline”, “reticular”, and “cuticular” drusen (Figure 1.9). Hard drusen 
are defined as small (<63 µm), round hemispherical structures with well-defined 
edges. In small numbers, hard drusen are not considered as risk factors for 
developing advanced AMD, which is defined as geographic atrophy or choroidal 
neovascularization.61-64 Individuals with large numbers of hard drusen have a 0.5% 
to 1.8% chance to develop advanced AMD within a follow-up period of 15 years.65 
Soft drusen, as compared to hard drusen, are typically larger in diameter (≥63 µm), 
more irregular in shape and have poorly demarcated boundaries which gives them a 
softer appearance. This drusen phenotype is formed by enlargement and fusion of 
a cluster of hard drusen, and therefore represents late-stage drusen progression.20 
In accordance with this advanced stage of drusen progression, eyes with soft drusen 
have an increased risk of 2.7% to 39.3% to develop advanced AMD within a follow-
up period of 15 years.65 Both hard drusen and soft drusen can undergo calcification 
(crystalline drusen), thus giving the druse a glistening appearance. Calcification of 
drusen usually presage drusen regression and the development of RPE atrophy 
(advanced AMD).66 
In contrast to the previous terms that describe a single druse, reticular drusen and 
cuticular drusen are drusen phenotypes defined by drusen patterns. Reticular drusen 
are defined as multiple “drusen” that form ill-defined networks of broad interlacing 
ribbons.67 They are identified easily with blue-channel examination, near-infrared 
photography, red-free photography, autofluorescence imaging and OCT.67-69 A unique 
histological feature of reticular drusen is that they are located internal  instead of 
external to the RPE.69 In this respect, the use of the term “drusen” is not entirely 
correct. However, similar to other drusen types, reticular drusen increase the risk 
on developing advanced AMD significantly.67,70-73 It is estimated that individuals with 
reticular drusen are at a 26% risk of developing advanced AMD during a follow-up 
period of 5 years.68 The last drusen phenotype, cuticular drusen, will be discussed 
into greater detail in the next section.
Cuticular drusen
The first report on cuticular drusen was published in 1977, when Donald Gass 
described a “new” clinical entity characterized by fundoscopic findings that included 
“innumerable, small (25 to 75 µm), round, uniformly sized, slightly raised, yellow, 
subretinal nodules, randomly scattered throughout the fundus”.74 In a follow-up study 
published eight years later,75 Gass and his associates referred to this entity as “basal 
laminar drusen” or “cuticular drusen” based on their interpretation of the data, 
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which suggested that the small subretinal lesions in this clinical entity were focalized, 
nodular thickenings of the basal lamina of the RPE. Recent studies, however, have 
revealed that these deposits are both ultrastructurally and compositionally identical 
to the drusen that are associated with AMD. Anatomically, these deposits are located 
between the basal lamina of the RPE and the inner collagenous layer of Bruch’s 
membrane,26 which was described previously by Müller as the inner cuticular zone.76 
Based on these histopathological features, the preferred term for this particular 
drusen phenotype is “cuticular drusen”.
Commonly appearing in early adulthood,77 this drusen phenotype is best appreciated 
on fluorescein angiography, which reveals the pathognomic “stars-in the-sky” 
or “milky-way” appearance in the fundus. These hyperfluorecent lesions start to 
fluoresce in the early arteriovenous phase of the fluorescein angiogram and typically 
outnumber the drusen discernable on ophthalmoscopy.77-80 Although the risk of 
developing advanced AMD in patients with cuticular drusen is currently unknown, 
the onset of advanced AMD seems to be on average a few years earlier as compared 
to the onset of advanced AMD in other drusen phenotypes.78,81-85
1.4.2 Advanced age-related macular degeneration
Advanced AMD can be classified into geographic atrophy and choroidal 
neovascularization (CNV). Geographic atrophy (“dry” AMD), which accounts 
for approximately 85% of all cases with advanced AMD, is characterized by the 
development of one or more sharply delineated areas of chorioretinal atrophy that 
usually start to develop in the region near the fovea without involving the foveal 
center.86-89 However, because these atrophic lesions tend to enlarge and coalesce 
steadily over a period of years, most patients will lose central vision in the late stages 
when the atrophy expands into the foveal center. 
The alternative form of advanced AMD, CNV (“wet” AMD), is characterized by the 
formation of abnormal new blood vessels from the choriocapillaris that grow through 
the Bruch’s membrane into the subretinal space and the retina. These fenestrated 
and friable new vessels leak serous fluid, lipids, and blood beneath and into the 
neural retina, with subsequent fibrous scarring. This process of neovascularization 
and fibrovascular scar formation can cause a rapid and severe loss of central vision 
in a matter of weeks or months.90 Whereas CNV accounts for only 15% of all cases of 
advanced AMD, more than 90% of AMD patients with severe loss of central vision 
manifest CNV.91
General introduction
32
1.4.3 Risk factors
Environmental risk factors
Although advanced age is the major risk factor associated with AMD,49 environmental 
and lifestyle factors may significantly alter individual risk. Cigarette smoking is the 
best characterized modifiable factor that has been consistently associated with 
a two- to three-fold increased risk for developing AMD.92 Oxidative stress and 
antioxidant depletion have been implicated in retinal damage from smoking, 
although the precise mechanism remains unclear.93,94 Other factors that have been 
reported to influence risk for AMD include obesity,95,96 sunlight exposure97 and a 
history of cardiovascular disease (e.g., hypertension).98 Regarding diet, omega 3 
polyunsaturated fatty acids, the carotenoids lutein and zeaxanthin, and antioxidants 
such as zinc, and vitamins A and E may protect against the development of AMD.99-
101 Differences in the prevalence of AMD between the two sexes, with a prevalence 
among females being greater than that among men,102 could reflect environmental 
as well as genetic risk factors.
Genetic risk factors 
The first evidence for the influence of the genetic make-up on AMD came from family 
and twin studies.103-107 First-degree relatives of patients with AMD are at increased 
risk for the disorder, compared to first-degree relatives in families without AMD.107 
In addition, they are affected at a younger age,108,109 and have an increased lifetime 
risk of an advanced form of AMD.109 In more recent efforts to reveal the underlying 
genetic modifiers in AMD, a number of high-risk SNPs have been identified in genes 
that encode components of the complement system, a part of the innate immune 
system. The most prominent is the Y402H SNP in the complement factor H (CFH) 
gene, producing a nearly three-fold increased risk of disease in individuals who 
harbor one copy of the Y402H SNP.110-112 Other genes of the complement system 
harboring confirmed risk alleles are complement component 2 (C2),113 complement 
factor B (CFB),113 complement component 3 (C3),114 complement factor I (CFI)115 and 
age-related maculopathy susceptibility 2 (ARMS2).116,117 Although the latter is not 
known to be part of the complement pathway itself, there is growing evidence that 
ARMS2 is associated with complement activation.117
Other biological pathways that harbor AMD-associated SNPs are the HDL cholesterol 
pathway, which includes the APOE,118,119 LIPC,120 CETP,121 ABCA1,121 FADS1_3,120 and 
LPL genes,121 and the extracellular matrix involving the COL8A1120 and COL10A1 
genes,122 and the TIMP3 gene.121 
1.4.4 Pathogenesis
The pathogenesis of AMD is not completely understood. Many theories exist, 
however, a common theme shared by most of these theories is the central role of 
inflammation and the immune system. Immune mechanisms and cellular interactions 
in AMD are similar to those seen in other diseases characterized by the accumulation 
of extracellular deposits such as atherosclerosis and Alzheimer’s disease.123 Evidence 
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is growing that the complement system plays a significant role in the pathogenesis 
of AMD.124 Inflammatory and immune-mediated events involving complement 
proteins have been implicated in the biogenesis of drusen.57 Consistent with this 
histopathological link is the genetic association between AMD and several variants 
in genes encoding complement components.110-116 
Complement system
The complement system is one of the first lines of defense in innate immunity and is 
important for microbial killing, immune complex handling, apoptotic cell clearance, 
tissue homeostasis and modifying the adaptive immune response.125,126 Critical to 
these functions is the triggering of a series of cascades that result in the formation 
of metastable protease complexes which ultimately form the membrane attack 
complex, also known as the terminal complement complex. In sequential order, 
this series of cascades can be divided in four main steps: initiation of complement 
activation, C3 convertase activation, C5 convertase activation, and terminal pathway 
activity with the assembly of the membrane attack complex (Figure 1.10).
Initiation of complement activation proceeds via either of three distinct pathways: 
the classical pathway, the lectin pathway and the alternative pathway. Current 
evidence suggests that the alternative complement pathway is most closely related 
to the pathogenesis of AMD. The initiation of this complement pathway depends on 
the constant low-grade activation by spontaneous hydrolysis of the internal thioester 
bond of C3, which results in the formation of the C3b-like molecule C3(H2O).127 
This initially generated hydrolyzed C3 then binds directly via its labile thioester to 
activating foreign or self-surfaces in the body.128 When C3(H2O) is bound to these 
surfaces, it interacts with complement factor B (FB), which is cleaved by complement 
factor D into two factors, Ba and Bb. The latter remains bound to C3(H2O) to form the 
initial fluid-phase C3 proconvertase C3(H2O)Bb. This C3 proconvertase constantly 
cleaves more C3 molecules generating C3b and is referred to as the “tick over” 
of the alternative pathway. The generated C3b then interacts with FB to form the 
more active alternative pathway C3 convertase (C3bBb). It is this self-propagation 
that results in an exponential amplification of the alternative complement pathway, 
necessitating tight control by either membrane-bound or soluble regulators.
Enzymatic inactivation of C3b into iC3b is the main mechanism of control of the 
alternative pathway. This step is mediated by four factors: circulating complement 
factor I (FI), a regulatory enzyme of the complement system, the plasma protein 
complement factor H (FH), and two cell-membrane proteins, complement receptor 
type 1 and membrane co-factor protein. FH is the main fluid-phase regulator, and in 
its absence the regulation of alternative pathway complement activation is severely 
disturbed. The FH protein is a potent inhibitor of the alternative complement 
pathway because it works through three mechanisms of action: it effectuates the 
decay of C3 convertase (C3bBb), it competes with FB in binding to C3b, and finally 
FH is a cofactor for the serine protease FI to allow the cleavage of C3b into the 
General introduction
34
inactive form iC3b.129 Mutations in the genes encoding these complement regulators 
are associated with the AMD subtype of cuticular drusen and will be discussed in 
Chapters 3 and 4 of this thesis.
Independent of the initiation of complement activation, all three complement 
pathways ultimately converge with the formation of C3 convertase (C4b2a or C3bBb). 
These C3 convertases cleave more C3 to C3a and C3b, allowing the binding of an 
additional C3b molecule to the C3 convertase complexes, leading to the formation 
of C3bBbb, the C5 convertase of the alternative pathway, or C4b2b3b, the C5 
convertase for the classical and lectin pathways.130 These C5 convertases then initiate 
the assembly of the membrane attack complex by cleavage of C5 to C5a and C5b. 
The newly formed C5b forms a tri-molecular complex by binding C6 and C7. After 
inserting into a cell membrane, this complex binds C8 and multiple C9 molecules. 
This results in the completion of the pore-forming membrane attack complex (C5b-
9) and ultimately in cell lysis.131,132
chapter one
Fig. 1.10. Schematic representation of the complement system. (A) Complement is initiated by three 
major pathways: 1) the alternative pathway, 2) the classical pathway and 3) the lectin pathway. (B) The 
three pathways initiate the formation of component 3 (C3) convertases. These enzymes cleave the 
central complement component C3 and generate the anaphylactic and antimicrobial peptide C3a and 
the opsonin C3b, which can be deposited onto any nearby surface. This activation is followed by an 
amplification reaction that generates additional C3 convertases and deposits more C3b at the local 
site. Subsequently, C3b is inactivated and sequentially degraded and the various degradation products 
mediate important effector functions. For example, C3b deposition on a surface results in opsonization, 
which allows for the interaction of C3b with specific host C3 receptors expressed on the surface of 
immune effector cells. (C) If activation progresses, a new enzyme, the C5 convertase is generated. C5 
convertase cleaves C5, releases the potent anaphylactic peptide C5a and generates C5b. (D) C5b can 
initiate the terminal pathway , which recruits the components C6, C7, C8 and C9 to the surface of the 
target and inserts the C9 complex as a into the membrane. The activated complement system generates 
multiple effector compounds that drive and orchestrate further immune reactions. (Figure derived from 
Zipfel et al., 2009142).
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1.4.5 Present and future therapeutic options for AMD
Preventive interventions
The prevention of AMD is mainly focused on diminishing risk factors that exacerbate 
oxidative stress. Cessation of cigarette smoking is recommended since its adverse 
association with advanced AMD is unequivocal. Supplementation with antioxidants, 
on the other hand, aims at counteracting the reactive oxygen species involved in 
oxidative stress. Well-known supplements used to prevent AMD progression are 
zinc and the macular carotenoids lutein and zeaxanthin.134 
The evidence as to whether diets rich in antioxidant micronutrients will prevent 
the development of AMD is less consistent. In 1997, the AREDS trial reported that 
supplementation with high doses of beta-carotene, vitamins C and E, and zinc 
reduced the relative risk of progression from early to advanced disease by about 
20%.135 However, high doses of dietary supplements, particularly beta-carotene, 
proved to be harmful to smokers and is not without risk.136 The benefits and harms 
of taking supplements need to be assessed for the individual patient. Accumulating 
evidence from longitudinal observational studies supports the view that retinal 
function may be improved or better maintained after supplementation with 
carotenoids and anti-oxidants.137
Palliative interventions
For patients with AMD who develop a CNV, monotherapy with an anti-vascular 
endothelial growth factor (anti-VEGF) drug is the current standard of care. Use of these 
biologicals in the management of neovascular AMD has led to the abandonment of 
laser-based treatments that were the standard treatment in the previous decades, 
and involved the ablation of the area of neovascularization with thermal laser or the 
induction of vascular thrombosis by photodynamic therapy (PDT). Although laser 
treatments were beneficial compared with the natural history of AMD, they did not 
generally result in vision gain on the long term.138,139 The subsequent introduction 
of PDT proved beneficial in the prevention of vision loss, but with the arrival of anti-
VEGF drugs, such as ranibizumab and bevacizumab, it became possible to regain 
visual acuity in patients with exudative AMD.140,141
For the dry form of AMD, characterized by geographic atrophy, there is currently no 
effective therapy. Advances in gene therapy and stem cell therapy have the potential 
to alleviate vision loss and the development of this end-stage AMD lesion in the 
near future. However, AMD is a complex disease and a thorough appreciation of the 
pathogenic mechanisms underlying its different clinical subtypes will be necessary 
to improve the current therapeutic options.
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1.5 Aims and outline of this thesis
The main objective of this thesis was to improve our clinical and genetic understanding 
of the cuticular drusen subtype of AMD. These insights can be used to improve 
the recognition of this subtype and to counsel patients and their families. We 
envision that the gained understanding of the pathogenic mechanisms will aid the 
identification of new therapeutic avenues for cuticular drusen and AMD as a whole.
Chapter 2 evaluates the AMD risk factors in the cuticular drusen subtype of AMD 
and compares the effect size of the risk factors to AMD in general.
Chapter 3 focuses on the clinical and genetic studies performed in 3 families with 
cuticular drusen. It describes the identification of novel mutations in the CFH gene, 
followed by a detailed description of the clinical features of individuals carrying 
these mutations.
Chapter 4 presents the identification of rare missense mutations in the CFI gene as 
a novel cause of AMD, followed by functional studies to investigate the impact of 
the mutations on protein expression and function. In addition, zebrafish models are 
used to evaluate the impact of the mutation on vascular architecture in vivo. 
Chapter 5 concerns an evaluation of drusen morphology over a period of 4 months 
in patients with cuticular drusen. Drusen that show a spontaneous change in volume 
over time are further analyzed according to a set of morphologic parameters to 
determine whether initial drusen morphology can predict the future course of drusen 
development. 
In Chapter 6, the studies described in this thesis are further discussed and placed in 
a broader perspective. A summary of the findings is provided in Chapter 7.
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Objectives: To assess the association of gender, cigarette smoking, body-mass 
index, and nine genetic risk variants with cuticular drusen (CD), a well recognized 
subtype of age-related macular degeneration (AMD).
Methods: A total of 757 patients with AMD, including 217 patients with CD, and 
553 control individuals were interviewed with a questionnaire and underwent an 
ophthalmic examination. Venous blood samples were obtained for genomic DNA 
extraction, and genotyping was performed of single nucleotide polymorphisms 
previously associated with AMD. Odds ratios were calculated for patients with CD, 
using unaffected control individuals as a reference. Furthermore, odds ratios in 
patients with CD were compared to those in patients with “non-CD” AMD.  
Results: The CD subtype of AMD was significantly associated with current smoking 
as well as variants in the complement factor H (CFH), age-related maculopathy 
susceptibility 2 (ARMS2), complement factor B/complement component 2 (CFB/
C2), complement component 3 (C3) and apolipoprotein E (APOE) genes. In patients 
with CD, the association with the CFH Y402H risk allele was significantly higher (P 
= 0.022), whereas the association with current smoking was significantly lower (P < 
0.001) than in the heterogeneous group of patients with “non-CD” AMD.
Conclusions: The AMD subtype of CD was associated with previously identified 
genetic AMD risk factors. However, the association with the CFH Y402H risk allele 
appeared to be stronger, whereas the association with smoking was less pronounced 
when compared to AMD as a whole. This study suggests a more important role for 
genetic factors than environmental factors in the development of this well-defined 
subtype of AMD. These findings stress the importance of detailed phenotyping 
in AMD to identify homogeneous AMD subtypes, which may be associated with 
different risk factors and disease mechanisms. Such studies will improve the accuracy 
of predictive models and the effectiveness of preventive and therapeutic options in 
AMD.
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Introduction
Age-related macular degeneration (AMD) is the most common cause of irreversible 
and progressive visual loss among the elderly in the Western world.1,2 The 
abnormalities of this disorder range from discrete drusen deposits and pigmentary 
changes in early AMD to geographic atrophy and/or choroidal neovascularization 
(CNV) in the advanced forms.
AMD is a clear example of a multifactorial disease, and a wide variety of risk factors 
have been associated with the development and progression of AMD. Advanced age, 
female gender, cigarette smoking, and a high body-mass index (BMI > 30) have been 
reported as the most consistently reproducible demographic and environmental risk 
factors in AMD.3-7 Familial aggregation analyses and twin studies have provided clear 
evidence of heritability, and more recently strong associations were found with the 
Y402H (rs1061170) polymorphism in the complement factor H (CFH) gene and with 
the A69S (rs10490924) polymorphism in the age-related maculopathy susceptibility 
2 (ARMS2) gene.8-12 These two allelic variants contribute to late AMD in more than 
80% of cases.13,14 Other genes that harbor established risk variants for AMD include 
the complement factor B (CFB), complement component 2 (C2), complement 
component 3 (C3), complement factor I (CFI), and the apolipoprotein E (APOE) 
genes.15-22
The fact that AMD is highly heterogeneous in its clinical presentation is well 
recognized. Nevertheless, most studies reporting on the influence of environmental 
and genetic risk factors analyzed the AMD phenotype as a whole, without attempting 
to determine these risk factors in more homogeneous subtypes of the disorder. 
Based on the clinically observed abnormalities, several subtypes of AMD may be 
recognized, including polypoidal choroidal vasculopathy, retinal angiomatous 
proliferation, and cuticular drusen (CD).23-29 The latter, also known as basal laminar 
drusen,30 is characterized by the fundoscopic findings of innumerable, small (25 
μm to 75 μm), uniformly sized, round drusen.31 Most commonly appearing in early 
adulthood, these drusen are easy visualized with fluorescein angiography (FA). In 
more advanced stages, the multitude of drusen produce a typical “stars-in-the-sky” 
appearance in early phases of the angiogram.32 Researchers have estimated that the 
CD phenotype comprises approximately 10% of the AMD spectrum.29
In the present study, we investigated whether the AMD subtype of CD displays 
different environmental and genetic risk factors than AMD as a whole.
association analysis of risk factors in cuticular drusen
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Methods
Subjects
In this study, we evaluated a total of 757 unrelated patients with AMD, including 217 
patients with CD, and 553 control individuals. All subjects were retrieved from the 
European Genetic Database (EUGENDA), a multicenter database for clinical and 
molecular analysis of AMD. In the current study, only Caucasian participants from the 
Nijmegen (the Netherlands) area participated.
Before being enrolled in EUGENDA, all subjects were interviewed with a questionnaire 
to document their medical history and lifestyle habits, such as BMI and smoking 
status. Subjects who reported a kidney disease were excluded from the study to 
preclude including patients with membranoproliferative glomerulonephritis (MPGN) 
type II. Pupillary dilatation was achieved with topical 1.0% tropicamide and 2.5% 
phenylephrine before retinal imaging. Digital non-stereoscopic 30° color fundus 
photography was performed with a Topcon TRC 50IX (Topcon Corporation, Tokyo, 
Japan). In addition, patients with AMD received FA and high-resolution Fourier-
domain optical coherence tomography (FD-OCT), performed with a combined 
confocal scanning laser ophthalmoscope/FD-OCT device (SPECTRALIS, Heidelberg 
Engineering, Heidelberg, Germany). 
Color fundus photographs of both eyes of all cases were evaluated by two independent 
reading center graders according to the standard protocol of the Cologne Image 
Reading Center and Laboratory (CIRCL). AMD was defined by using international 
standards as described previously.33 Individuals of similar age as the AMD cases and 
who exhibited no signs of AMD in either eye were collected as controls. The CD 
subtype was defined as a symmetric distributed pattern between both eyes of at least 
50 scattered, uniformly-sized, small (25 μm to 75 μm) hyperfluorescent drusen on FA 
in each eye, of which a minimum of 20 drusen are located outside the Wisconsin 
age-related maculopathy grading template.34 After the grading was completed, the 
AMD cohort was divided into a cohort of patients with the AMD subtype of CD and 
a group of patients with “non-CD” AMD.
This study was reviewed and approved by the local institutional review boards and 
adhered to the tenets of the Declaration of Helsinki. Written informed consent was 
obtained from all individuals before they participated in the study. 
Single nucleotide polymorphism genotyping
Genomic DNA was isolated from peripheral blood leukocytes using standard 
techniques and stored at −20 °C. Genotyping of single nucleotide polymorphisms 
(SNPs) in the CFH (rs1410996), ARMS2 (rs10490924), CFB (rs4151667), C2 (rs9332739), 
C3 (rs2230199), CFI (rs10033900), and APOE (E2 allele; rs7412 and E4 allele; 
rs429358) genes in the “non-CD” AMD, CD, and control cohorts were performed as 
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previously described.35 The CFH variant Y402H (rs1061170) was analyzed with direct 
sequencing of PCR products using forward primer 5’-TCA TTG TTA TGG TCC TTA 
GG-3’ and reverse primer 5’-AAA GAC ATG AAC ATG CTA GG-3’. These nine SNPs 
were selected because they were previously associated with AMD.8-12,15-22 Fourteen 
percent of the genotypes were done in duplicate, resulting in a concordance of 
≥ 99.9%.
Statistics
Genotype frequencies in the control individuals were tested for Hardy–Weinberg 
equilibrium. Baseline and clinical characteristics were analyzed with standard 
descriptive statistics, and differences in gender, smoking status, and BMI were 
analyzed with a multivariate logistic regression analysis to adjust for the covariates 
age, gender, BMI, and smoking status where applicable. Subsequently, to study 
the associations of allele frequencies for AMD-associated SNPs among the “non-
CD” AMD cohort, the CD cohort, and the controls, a multivariate logistic regression 
analysis was performed to adjust for the covariates age, gender, smoking status, and 
BMI. The differences between the three cohorts are presented as odds ratios (ORs) 
with 95% confidence intervals (95% CIs).
Data analysis was performed using SPSS software, version 18.0 (SPSS Inc., Chicago, 
IL). The reported P values are two-sided, and a value of < 0.05 was considered 
statistically significant.
Results
Baseline demographics and risk allele frequencies of the “non-CD” AMD (n = 540), 
CD (n = 217), and control (n = 553) cohorts are depicted in Table 2.1 and Table 2.2. 
The mean age was 76.7 years (range 55–94; standard deviation [SD] 7.4) in the “non-
CD” AMD cohort, 69.3 years (range 50–91; SD 10.4) in the CD cohort, and 73.1 years 
(range 55–92; SD 6.3) in the controls.
Current smoking showed an association with CD (P = 0.032; OR: 2.06; 95% CI: 1.07–
4.00), and this association was significantly lower (P < 0.001; OR: 0.32; 95% CI: 0.17–
0.58) compared to the “non-CD” AMD cohort. Female gender showed a trend (P = 
0.086), and no association with BMI was found for CD.
All genotype frequencies conformed to Hardy–Weinberg equilibrium in the control 
cohort. The risk allele frequency of the CFH Y402H (rs1061170) variant was 64.1% in 
the CD cohort, which closely approximates the prevalence reported previously in 
patients extensively affected with CD.25 A significantly higher CFH Y402H risk allele 
frequency was found in the CD cohort when compared with the control cohort (P 
< 0.001; OR: 2.88; 95% CI: 2.23–3.73), and when compared to the “non-CD” AMD 
cohort (P = 0.022; OR: 1.35; 95% CI: 1.04–1.74).
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The risk allele frequencies of the ARMS2 (rs10490924), CFH (rs1410996), C3 (rs2230199), 
and APOE E2 (rs7412) variants were significantly higher in the CD cohort compared 
to the control cohort, and the protective allele frequencies of the C2 (rs9332739), 
CFB (rs4151667), and APOE E4 (rs429358) variants were significantly lower in the CD 
cohort compared to the control cohort. These odds ratios were comparable with 
the “non-CD” AMD cohort, and no significant differences were observed between 
the CD and “non-CD” AMD cohort for these SNPs. No association with the CFI 
(rs10033900) risk allele was found in the CD cohort.
Discussion
The clinical spectrum of AMD is broad, and this clinical heterogeneity will influence 
the results of association studies on demographic, environmental, and genetic 
risk factors. Improved phenotyping will increase the power of association studies 
in predictive models for AMD,36,37 and will lead to a better understanding of the 
pathogenesis of the different AMD subtypes.
In the present study, we focused on CD, a well-defined subtype of AMD. The 
relatively early onset of CD, as well as the observation that the CD phenotype is often 
clustered in families, implies a greater contribution of the genetic constitution when 
compared to AMD in general.23,25,29 This is further supported by our observation that 
one of the most important environmental risk factors, current smoking, showed a 
significantly lower association with CD than with “non-CD” AMD. The latter may also 
imply that the general advice to patients with AMD for cessation of smoking could 
be of limited effect in individuals with the CD subtype of AMD. However, this does 
certainly not mean that cessation of smoking should not be encouraged in patients 
with CD as current smoking could worsen the natural history of the disease.
Genetic evaluation of our CD cohort showed significant associations between this 
AMD subtype and variants in the CFH, ARMS2, CFB, C2, C3, and APOE genes. Risk 
alleles of the rs1410996 (CFH), rs10490924 (ARMS2), rs4151667 (CFB), rs9332739 (C2), 
rs2230199 (C3), rs7412 (APOE E2), and rs429358 (APOE E4) SNPs were significantly 
associated with CD. However, no significant differences for the previously mentioned 
risk alleles were observed between patients with CD and AMD in general. This 
suggests that there is a shared genetic background between AMD in general and CD, 
which has also been described for other AMD subtypes such as polypoidal choroidal 
vasculopathy and retinal angiomatous proliferation.24,26,28,38 A lack of association 
between the rs10033900 (CFI) risk allele and CD could be due to insufficient power 
in our study to detect small effects. However, the debate over whether this variant 
is associated with AMD continues as conflicting results have been observed.16,17,39 
Additional studies are needed to clarify the nature of the association between AMD 
and this particular variant near the CFI gene.
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A previous study of Caucasian patients who were severely affected with CD 
demonstrated a strong association with the Y402H (rs1061170) variant in the CFH 
gene.25 Our study shows that, in spite of the various stages of the CD phenotype 
included in our cohort, patients with CD are 1.35 times more likely to carry the 
CFH Y402H risk allele compared to patients with “non-CD” AMD. This higher 
allele frequency of the CFH Y402H risk allele in patients with CD suggests that 
activation of the alternative pathway of the complement system may play a larger 
role in the pathogenesis of the CD phenotype than in the remainder of the AMD 
phenotypes.40,41 This is supported by our previous studies that identified rare 
pathogenic CFH mutations in a subset of families with CD.23,29 These mutations have 
not been found in patients with AMD who did not display the CD phenotype. In 
patients with MPGN type II, or dense deposit disease, CFH mutations and disturbed 
serum complement activation levels have also been demonstrated.42 Remarkably, 
almost 70% of individuals with MPGN type II develop extensive drusen in a pattern 
matching that of extensive CD during their second decade of life.43 In approximately 
10% of these patients, CNV and/or central geographic atrophy may develop at a 
relatively young age.44-46 These alterations of the complement system may contribute 
to the relatively early onset of CD.
The increased insights into the mechanisms underlying AMD have led to possible 
therapeutic options that have recently entered phase 1 clinical trials.47 One option 
may be the use of specific anti-inflammatory molecules that block complement 
activation.47 These complement inhibitors may especially benefit individuals with the 
CD subtype of AMD, where complement activation appears more fundamental to 
the disease process compared to AMD in general.
In conclusion, the analysis of a large cohort of the CD subtype of AMD has revealed 
that genetic risk factors affecting the complement system are especially prevalent 
in these patients. In addition, the environmental risk factor of smoking appears less 
influential than in AMD in general. These findings stress the importance of detailed 
phenotyping in AMD to identify homogeneous AMD subgroups, which may be 
associated with different risk factors and disease mechanisms. Such studies may 
improve the accuracy of predictive models and the effectiveness of preventive and 
therapeutic options in AMD.
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Objectives: To identify novel complement factor H (CFH) gene mutations and to 
specify the clinical characteristics in patients with cuticular drusen (CD), a clinical 
subtype of age-related macular degeneration.
Methods:Twenty-one probands with CD were included in this study. The ophthalmic 
examination included nonstereoscopic 30° color fundus photography, fluorescein 
angiography, and high-resolution spectral-domain optical coherence tomography. 
Renal function was tested by measurement of serum creatinine and urea nitrogen 
levels. Venous blood samples were drawn for genomic DNA, and all coding exons 
and splice junctions of the CFH gene were analyzed by direct sequencing.
Results: In 3 families, we identified novel heterozygous mutations in the CFH gene: 
p.Ile184fsX, p.Lys204fsX, and c.1697-17_-8del. Ten of 13 mutation carriers displayed 
the CD phenotype with a wide variety in clinical presentation, ranging from limited 
macular drusen to extensive drusen in the posterior pole as well as the peripheral 
retina. Two patients with CD developed endstage kidney disease as a result of 
membranoproliferative glomerulonephritis type II.
Conclusions: The early-onset CD phenotype can be caused by heterozygous 
mutations in the CFH gene. Because some patients with CD are at risk to develop 
membranoproliferative glomerulonephritis type II, we recommend that patients with 
extensive CD undergo screening for renal dysfunction.
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Introduction
Age-related macular degeneration (AMD) is the most common cause of irreversible 
vision loss in the Western world among people 65 years or older, with a prevalence 
of advanced AMD of 12% after 80 years of age.1 Several risk factors for the 
development of AMD have been recognized, including modifiable risk factors, such 
as smoking, higher body mass index, and low dietary intake of antioxidants and zinc. 
Nonmodifiable risk factors include advancing age, female sex, white race, and a 
great variety of genetic factors.2 
Genes involved in the complement system have received heightened attention 
because single-nucleotide polymorphisms in the genes encoding complement factor 
H (CFH), complement factor B (CFB),3,4 complement factor I (CFI),5 component 2 (C2),3 
and component 3 (C3)6-9 are associated with increased risk of AMD. A particularly 
strong association has been reported by many studies for a nonsynonymous single-
nucleotide polymorphism in CFH that encodes a tyrosine-to-histidine missense 
variant at amino acid 402 (p.Tyr402His). Carriership of this variant increases the risk 
for AMD with an odds ratio ranging from 2.45 to 7.40 and may account for more than 
50% of the attributable risk of AMD.10-12 
The complement factor H (FH) protein inhibits the alternative pathway by competing 
with complement factor B in binding to C3b, accelerating the decay of the alternative 
pathway C3 convertase and acting as a cofactor for the factor I–mediated proteolytic 
inactivation of C3b.13-15 By this mechanism, FH is essential to maintain complement 
homeostasis in plasma and to restrict complement activation on complement 
activating self-surfaces such as the retinal pigment epithelium.
Age-related macular degeneration is characterized by multiple heterogeneous 
subtypes, with drusen as the hallmark lesions and usually the first clinical finding.16-21 
Cuticular drusen (CD), also termed basal laminar drusen or early adult onset, 
grouped drusen, is one of the subtypes in the AMD spectrum.22 The CD phenotype 
shows characteristic innumerable, small, subretinal, raised yellow drusen that are 
hyperfluorescent on fluorescein angiography, resulting in a typical “stars-in-the-sky” 
appearance.23 The CD phenotype is also associated with the p.Tyr402His variant in 
the CFH gene, with a risk allele frequency up to 70% vs 55% in “typical” AMD-
affected individuals.24 Boon and colleagues25 found an association of compound 
heterozygous variants in the CFH gene with CD. Specific mutations and variants in 
the CFH gene are associated with a broad range of phenotypes, from early-onset 
renal diseases with high mortality rates to disorders limited to the eye, such as 
AMD.22 Some patients have concurrent renal and retinal abnormalities.26-29 It has been 
postulated that the type, onset, and severity of renal and/or retinal abnormalities 
show a considerable degree of genotype-phenotype correlation.22
The purposes of this study were to identify novel CFH gene mutations and to specify 
the clinical characteristics in patients with CD.
cuticular drusen caused by a mutation in the cfh Gene
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Methods
In this study, we included 21 probands diagnosed as having AMD who were noted 
on initial examination to have CD on fluorescein angiography and 192 ethnically 
matched control subjects of similar age who showed no signs of maculopathy. 
Informed consent was obtained from all subjects after explanation of the nature and 
possible consequences of the study. We conducted the study in accordance with 
the tenets of the Declaration of Helsinki, and it was approved by the Committee on 
Research Involving Human Subjects at the Radboud University Nijmegen Medical 
Center, Nijmegen, the Netherlands.
Ophthalmic examination
Ophthalmic examination of the subjects included Early Treatment Diabetic 
Retinopathy Study visual acuity and slitlamp biomicroscopy after pupil dilatation. 
Digital nonstereoscopic 30° color fundus photographs were taken with a digital 
fundus camera (Topcon TRC 50IX; Topcon Corporation). To confirm the diagnosis 
of CD, we performed fluorescein angiography and high-resolution Fourier-
domain optical coherence tomography using the combined confocal scanning 
laser ophthalmoscope/Fourier-domain optical coherence tomography device 
(Spectralis; Heidelberg Engineering). In the early stages, the diagnosis was based 
on fluorescein angiographic confirmation of innumerable small drusen in the 
macula and/or peripheral retina, giving a symmetrically distributed pattern of 
innumerable, scattered, uniformly sized, small (25 to 75 μm) hyperfluorescent lesions 
in both eyes. The occurrence of confluent (soft) drusen in the macular region and 
the subsequent development of a drusenoid pigment epithelial detachment are 
considered characteristic for the later stages of this disease. A final feature is the 
central geographic atrophy of the retinal pigment epithelium, frequently observed 
after resolution of the drusenoid pigment epithelial detachment or the development 
of choroidal neovascularization (CNV).25
Renal function
Renal function was tested by measuring serum creatinine and urea nitrogen levels. 
The following ranges were considered for normal kidney function: 0.68 to 1.24 mg/
dL for creatinine and 7.0 to 19.6 mg/dL for urea nitrogen. (To convert creatinine to 
micromoles per liter, multiply by 88.4, and to convert urea nitrogen to millimoles per 
liter, multiply by 0.357.)
Mutation analysis
Venous blood samples were drawn for genomic DNA extraction from peripheral 
blood leukocytes. The DNA was analyzed for mutations in CFH (NCBI Entrez Gene 
NM_000186) by polymerase chain reaction amplification of the 22 coding exons 
and splice junctions. Reactions were performed using standard protocols. (Primer 
sequences and polymerase chain reaction conditions are available from the authors 
on request.) Amplification products were purified, quantified on a 2% agarose gel, 
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and diluted for direct sequencing on an automated sequencer (BigDye Terminator, 
version 3 on a 3730 DNA analyzer; Applied Biosystems, Inc). Sequences were 
assembled using proprietary software (ContigExpress, Vector NTI suite, version 
10.0; InforMax, Inc). Each of the novel mutations identified was validated through an 
independent polymerase chain reaction and a sequencing reaction.
Results
In 3 of the 21 probands, we identified novel heterozygous mutations in the CFH gene: 
2 frameshift mutations in exon 5 and 1 splice-site mutation in the spliceacceptor site 
of exon 12 (Figure 3.1). None of these CFH mutations were identified in 192 control 
subjects who had no signs of maculopathy, and no nonsense, frameshift, or splice-
site mutations were identified in 369 ethnically matched controls from our in-house 
exome database.
The probands who carried a mutation in the CFH gene could not be distinguished 
clinically from the probands who did not carry a CFH mutation (Table 3.1). Of the 
20 additional family members who underwent screening for the novel CFH gene 
mutations, 10 were shown to carry the same mutation as the proband, of whom 7 
proved to be affected by CD (Figure 3.2 and Table 3.2). However, only the probands 
of the 3 families noticed visual loss before the diagnosis of CD was established.
Of all the patients carrying a mutation in CFH, 5 (in families A and B) were compound 
heterozygous for the novel CFH mutation together with the AMD risk allele 
p.Tyr402His in the CFH gene. The other 8 patients (in families A, B, and C) did not 
carry the p.Tyr402His risk allele or carried it heterozygously on the same allele as the 
mutation. An overview of the clinical and genetic characteristics of the 3 families is 
given in Table 3.2.
cuticular drusen caused by a mutation in the cfh Gene
Figure 3.1. Sequences of heterozygous mutations detected in the CFH gene. For each CFH mutation, 
the chromatogram corresponding to the DNA sequence surrounding the mutation in CFH is shown. 
MUT indicates mutated CFH allele; WT, wild-type CFH allele.
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Family A
In family A, we identified the heterozygous c.550delA; p.Ile184fsX frameshift mutation 
in exon 5. This mutation occurs in the third short consensus repeat of the FH protein.
The proband of family A (A-II:3) first noticed metamorphopsia and a decrease in 
visual acuity in both eyes at age 56 years. Ophthalmoscopy revealed extensive small 
and large confluent drusen in the posterior pole with a drusenoid pigment epithelial 
detachment in the macula of both eyes (Figure 3.3B and H). Among the affected 
siblings of the proband, patient A-II:1 (aged 64 years) showed hard drusen in the 
Figure 3.2. Molecular genetic analyses of the CFH gene in families affected with cuticular drusen (CD). 
Squares indicate men; circles, women; slashes, deceased family members; black symbols, patients with 
CD; shaded symbols, patients who display drusen but without CD; numbers in the pedigree symbols, 
current age (in years); plus signs, the wild-type allele; 402H, the CFH Y402H risk allele; and 402Y, the 
CFH wild-type allele. Mutations are in red, risk alleles in orange, and wild-type alleles in black. (A) All 
individuals affected by CD were heterozygous for the p.Ile184fsX frameshift mutation with the exception 
of the youngest mutation carrier, who had only some soft peripheral drusen at the time of examination. 
(B) All individuals carrying the p.Lys204fsX frameshift mutation were affected by CD. (C) Two carriers (C-
II:2 and C-III:1) of the c.1697-17_-8del frameshift mutation did not display CD.
A
C
B
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midperipheral retina, mostly located temporal to the fovea, whereas patient A-II:5 
(aged 61 years) had dense, macular, small and soft confluent drusen (Figure 3.3A 
and C). Small hard drusen were seen in the peripheral retina of patient A-III:1 (aged 
31 years) and A-III:2 (aged 27 years), with increasing numbers of these peripheral 
drusen with increasing age (Figure 3.3D, E, and G). Additional macular hard drusen 
were observed only in the oldest mutation carrier of the third generation (A-III:1) 
but to a lesser extent compared with his father (A-II:1). Patient A-III:4, the youngest 
mutation carrier in this family (aged 18 years) had some soft drusen in the peripheral 
retina but no hard drusen as were found in other family members carrying the 
c.550delA mutation (Figure 3.3F).
Family B
In family B, we identified the heterozygous c.607-610dupCCAA; p.Lys204fsX 
frameshift mutation in exon 5. As was the case for the c.550delA mutation in family 
A, this mutation also occurs in the region of the third short consensus repeat in the 
FH protein.
Patient B-II:1, the proband of family B, first noticed visual loss, associated 
metamorphopsia, and small central scotomas in both eyes at age 47 years. The 
proband and her affected siblings (B-II:4 and B-II:6) showed an equivalent CD 
phenotype of innumerable macular hard and soft drusen, with small hard drusen 
extending toward the peripheral retina that were symmetrical in both fundi (Figure 
3.4). The hard drusen in the peripheral retina had only a thin hyperpigmented border. 
Three years after the initial visual complaints, the proband reported increasing 
metamorphopsia and a rapid decrease in visual acuity from 20/20 to 20/67 of the left 
eye due to classic CNV in the left eye. This neovascularization was treated successfully 
during a period of 3 months with 3 intravitreal injections of bevacizumab, 0.05 mL (25 
mg/mL), at an interval of 4 weeks, resulting in increased visual acuity to 20/24 in that 
eye for 2 years as of the last examination.
Family C
In family C, we identified 3 individuals with the heterozygous CFH gene mutation 
(c.1697-17_-8del) in the splice-acceptor site. This mutation is predicted to abolish 
the splice-acceptor site of exon 12 of the CFH gene given that the splice prediction 
score is reduced from 0.62 to 0 (as calculated by the splice-site prediction program 
NNSPLICE, version 0.9; http://www.fruitfly.org/seq_tools /splice.html). 
Only patient C-II:4 was affected with CD. He reported a rapid decrease in visual 
acuity from 20/20 to 20/35 and metamorphopsia of the right eye at age 55 years. 
Both fundi showed a pigment epithelial detachment and pigmentary changes in 
the macular area, together with numerous small hard drusen in the midperipheral 
retina, mostly located temporal to the fovea. The right eye also showed a large area 
of parafoveal subretinal hemorrhage (Figure 3.5A and B). In both eyes, fluorescein 
angiography revealed more dense and well-circumscribed hyperfluorescent CD than 
were seen during direct ophthalmoscopy. In addition, the angiography revealed 
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parafoveal occult CNV in the right eye. This patient was treated successfully with 
4 intravitreal injections of bevacizumab, 0.05 mL (25 mg/mL), during a period of 
6 months, resulting in an increased and stabilized visual acuity of 20/20 without 
metamorphopsia for 3 years to date. 
A renal biopsy in patient C-II:4 at 27 years of age showed MPGN type II, resembling 
the findings in patient B-II:1. At age 46 years, end-stage kidney disease and 
subsequent renal failure necessitated a renal transplant. At the time of the most 
recent ophthalmic investigation, at age 58 years, there was no hematuria or 
proteinuria; the serum creatinine level was 1.10 mg/dL. In the 2 other carriers (C-II:2 
and C-III:1) of the c.1697-17_-8del mutation, we observed no fundus abnormalities 
and no signs of renal failure on blood test results.
Discussion
A subgroup of approximately 10% of patients with AMD are found to have CD at the 
initial examination, that is, innumerable small hard drusen throughout the fundus 
that are hyperfluorescent on fluorescein angiography, resulting in a typical stars-in-
the-sky appearance (J.P.H.V, C.J.F.B., L.H.H., B.J.K., A.I.D., and C.B.H., unpublished 
data, January 2012). The age at onset of CD is typically earlier than that for regular 
AMD, and CD are often observed in asymptomatic family members.25 The location 
and histopathological composition of CD appear to be identical to the drusen found 
in typical AMD.30 A common mechanism of drusen biogenesis is therefore likely. 
An association of the p.Tyr402His variant in the CFH gene with both AMD and 
the subtype of CD has been previously described and confirmed by several 
studies.10-12,24,31 In addition, Boon and coworkers25 were the first to find pathogenic 
heterozygous mutations in the CFH gene in association with the CD phenotype. 
In their study, the development of CD in individuals who carry a CFH mutation on 
one allele in combination with the presence of the p.Tyr402His variant on the other 
allele is described. We confirm this disease-causing model by heterozygous CFH 
gene mutations in a subgroup of patients affected with CD. However, the mode of 
inheritance of these mutations was not apparent in any of the families. Our study 
was not consistently in accordance with the suggested disease model of compound 
heterozygosity with the p.Tyr402His variant25 because 5 of 10 patients did not carry 
the CFH mutation in association with the p.Tyr402His variant on the other allele. 
However, we cannot exclude that heterozygous CFH mutations will cause CD and/or 
MPGN type II only when coinherited with as-yet unidentified variants in other genes.
The segregation of mutations in families A and B appears to be consistent with an 
autosomal dominant inheritance pattern. At age 18 years, the youngest member 
of family A (A-III:4), who carries a CFH gene mutation, showed only peripheral 
soft drusen without the typical hard drusen seen in patients with CD. Because 
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Figure 3.3. Retinal phenotypes of patients carrying the CFH p.Ile184fsX frameshift mutation. Fundus 
photography of the right eyes showed extensive hard drusen in midperipheral retina, mostly located 
temporally in patient A-II:1 (A); extensive soft, hard, and crystalline drusen scattered throughout the 
fundus in patient A-II:3 (B); and macular hard and soft drusen in patient A-II:5 (C). The green line indicates 
the optical coherence tomography section. Clustered groups of hard drusen (white arrowheads) were 
seen in the peripheral retina of patient A-III:1 (D) and patient A-III:2 (E) by fundus photography. In patient 
A-III:4, fundus photography showed soft drusen in the peripheral retina (F). Fluorescein angiography 
of the right eye of patient A-III:1 revealed more tiny hyperfluorescent drusen (G) than the number seen 
on color photography (D) in the peripheral retina. Optical coherence tomography (oblique section) of 
patient A-II:2 showed small dome-shaped elevations of the retinal pigment epithelium (H).
the formation of drusen is related to age, this patient may develop more drusen 
in the future in accordance with the CD phenotype. In family C, 1 individual of 
the 3 mutation carriers was affected, suggesting reduced penetrance of the CFH 
mutation or digenic/multigenic inheritance of variants in other genes. Alternatively, 
it is possible that a combination of genetic and acquired defects in the complement 
system may cause the disease, as has been demonstrated for MPGN.32,33 
A B C
D E F
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Figure 3.4. Retinal phenotypes of patients carrying the CFH p.Lys204fsX frameshift mutation. 
Fundus photography of the right eyes showed extensive drusen in the posterior pole extending to 
the peripheral retina of patients B-II:1 (A), B-II:4 (B), and B-II:6 (C). The green line indicates the optical 
coherence tomography section. Fluorescein angiography of patient B-II:4 showed similar but more 
numerous lesions (D) compared with color photography (B). Optical coherence tomography (oblique 
section) showed small dome-shaped elevations of the retinal pigment epithelium (E). 
A B C
D E
Figure 3.5. Retinal phenotype patient C-II:4, carrier of the CFH c.1697-17_-8del splice-acceptor 
site mutation. Fundus photography of the right eye showed, besides the extensive drusen in the 
posterior pole, a subretinal hemorrhage (A), which is clearly visualized with fluorescein angiography 
at age 55 years (B). At age 58 years, fundus photography showed large, soft, confluent macular drusen 
surrounded by many hard drusen in the right eye (C). Fluorescein angiography at age 58 years showed 
densely packed hyperfluorescent drusen in the posterior pole of the right eye (D). Optical coherence 
tomography (oblique section) showed the density of the drusen by the dome-shaped elevations of the 
retinal pigment epithelium (E).
A B C
D E
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Together with a previous report on CD caused by CFH gene mutations,25 our findings 
suggest that only patients having specific gene mutations will develop this clinical 
phenotype of CD or have a greater genetic predisposition to develop CD. This is in 
contrast to typical AMD, which is a multifactorial disorder caused by accumulating 
genetic and environmental risk.3-8,11,34 This also might be a plausible explanation for 
the earlier onset of CD compared with typical AMD. In our study, the 10 affected 
individuals with CD who carried mutations in the CFH gene showed a heterogeneous 
clinical presentation. A robust genotype-phenotype correlation of the severity of the 
disease is therefore not possible because only the identified CFH mutations were 
taken into consideration. 
Besides CD, specific mutations in the CFH gene can also cause MPGN type II (dense 
deposit disease).35 However, the mutations we describe in this study are novel and, 
to our knowledge, have never been identified in patients with MPGN type II. To 
date, only 9 patients with MPGN type II have been reported to carry CFH mutations, 
and nearly all of them were homozygous or compound heterozygous for missense 
mutations in CFH.36,37 Only 1 patient was reported to carry a single heterozygous 
missense mutation and to develop late-onset MPGN type II and CD.38 Because of 
the relatively late onset of MPGN type II in the 2 patients (B-II:1 and C-II:4) of our 
families, we reason that single heterozygous mutations in CFH may cause late-onset 
MPGN type II. Given that patient B-II:1 had early-onset CD at the initial examination 
before renal disease was diagnosed, we recommend that patients with extensive 
early-onset CD undergo screening afor renal dysfunction. Despite urea and creatinine 
clearance within reference limits, MPGN and future renal dysfunction might develop 
because MPGN may be at a subclinical stage.39 
Fundus changes in patients with MPGN type II vary from pigmentary changes 
and CD to larger soft drusen and CNV, finally leading to visual loss.27,28,40,41 The 2 
cases reported in our study are the second and third reported in the literature who 
developed a triad of MPGN type II, CD, and CNV caused by a specific mutation in 
CFH.38 In both cases, the CNV was effectively treated with intravitreal injections of 
bevacizumab. 
With upcoming treatment modalities to target specific components of the 
complement system, early identification of the CD subgroup of patients with AMD 
becomes relevant. The strong association of this group of patients with complement 
abnormalities may translate into a better response to complement-blocking therapy 
than among patients with AMD in general. Treatment with a humanized monoclonal 
antibody that blocks complement activity was shown to be successful in a patient 
with atypical hemolytic uremic syndrome.42-46 In 30% of all patients with atypical 
hemolytic uremic syndrome, CFH gene mutations are the cause of the disease. 
This manifests as a loss of function of CFH, resulting in increased activity of the 
complement system’s alternative pathway.47-49 Humanized monoclonal antibodies 
can inhibit the overactivated complement system. For this reason, humanized 
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monoclonal antibody seems to be a rational candidate treatment for patients with 
CD caused by mutations in the CFH gene.
In summary, our findings confirm the important role of heterozygous mutations in 
the CFH gene in the development of CD. The genotype-phenotype correlation 
is not straightforward, and other genetic and possibly environmental factors may 
contribute to the development or severity of the disease. We recommend monitoring 
the renal function in patients with extensive CD because some of these patients 
may develop MPGN type II. Conversely, ophthalmic screening for CD in patients 
with MPGN type II is recommended because of the risk of developing CNV and/or 
geographic atrophy. The association of heterozygous CFH mutations and presumed 
ensuing complement dysfunction in patients with AMD who also have CD provides 
us with a promising target for future treatments.
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Up to half of the heritability of age-related macular degeneration (AMD) is explained 
by common variants. Here, we report the identification of a rare, highly penetrant 
missense mutation in CFI encoding a p.Gly119Arg substitution that confers a high 
risk of AMD (P = 3.79 x 10-6, odds ratio = 22.20; 95% confidence interval 2.98-
164.49). Plasma/serum of cases carrying the p.Gly119Arg substitution mediated the 
degradation of C3b both in the fluid phase and on the cell surface at a lower level 
compared to controls. Recombinant protein studies revealed that the p.Gly119Arg 
mutant protein is both expressed and secreted at lower levels than wildtype protein. 
Consistent with these findings, 119Arg-encoding human mRNA had reduced activity 
compared to 119Gly in regulating vessel thickness and branching in the zebrafish 
retina. Taken together, these findings demonstrate that rare, highly penetrant 
mutations contribute to the genetic variance of AMD, with implications for predictive 
testing and personalized treatment.
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Age-related macular degeneration (AMD) is the most common cause of blindness 
among the elderly in the industrialized world.1,2 Genome-wide association studies 
(GWAS) revealed that common variants in or near genes within the complement 
cascade, high-density lipoprotein cholesterol pathway, extracellular collagen matrix, 
and vascular endothelial growth factor are associated with AMD.3-6 Combined, 
these variants explain 50% of the heritability of AMD.6-10 A fraction of the “missing 
heritability” in AMD may be explained by rare, highly penetrant variants.11-14
To explore the role of rare, highly penetrant variants in AMD, and to provide direct 
causal evidence for particular genes and their protein products, we focused on CFI, 
a gene that encodes Factor I (FI), a serine protease that circulates in its inactive form 
and can inactivate all complement pathways by cleaving the α’ chain of activated 
complement factors C3b and C4b.15,16 The importance of this FI-mediated regulatory 
mechanism is highlighted by the fact that rare CFI variants predispose to diseases such 
as atypical hemolytic uremic syndrome (aHUS)17 and systemic lupus erythematosus.18 
The hypothesis that altered FI function increases AMD risk has been raised,19 and 
an association between AMD and a haplotype block spanning the last two exons 
of CFI and the adjacent PLAG12A transcript was reported.20 However, in several 
GWAS, the most significant associations at this locus were reported for SNPs that are 
located downstream of CFI and in the adjacent PLAG12A and CCDC109B genes.3,5,6 
Therefore, these studies cannot distinguish between the involvement of PLAG12A 
or CCDC109B — rather than CFI — as the source of the association signal. 
Methods
Ethics Statement
This study was conducted in accordance with the tenets of the Declaration of Helsinki 
and was approved by the Institutional Review Board of the participating centers. All 
subjects provided signed informed consent for participation in the study and the use 
of their blood and DNA for AMD research. 
Study sample descriptions
Case definitions. Each subject was either clinically evaluated by dilated slit-lamp 
biomicroscopy and non-stereoscopic color fundus photography or assessed by 
reviewing the full ophthalmologic medical records. Cases in the EUGENDA, Baltimore 
and Rotterdam collections had either early AMD (stage 2; soft indistinct drusen (≥ 
125 µm) only, reticular drusen only or soft indistinct drusen (≥ 63 µm) with pigmentary 
irregularities or stage 3; soft indistinct drusen (≥ 125 µm) or reticular drusen with 
pigmentary irregularities) or advanced AMD (stage 4; central chorioretinal atrophy 
or choroidal neovascularization) according the Rotterdam classification (Table 4.1).21 
All subjects were classified based on the eye with the more advanced diagnosis. 
Control subjects did not have AMD (stage 0; no or only small hard drusen) in either 
eye and exhibited no other macular pathology. Individuals with AMD stage 1 (soft 
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2 3 4
1. EUGENDA-discovery 8 (9.5%) 27 (32.1%) 49 (58.3%) - 1 2
2. EUGENDA-replication 151 (14.9%) 50 (4.9%) 813 (82.4%) - 4 7
3. Baltimore-replication 65 (9.1%) 143 (20.0%) 507 (70.9%) - - 2
4. Rotterdam Study I-replication 799 (61.0%) 298 (22.8%) 213 (16.3%) - 3 -
5. Rotterdam Study II-replication 219 (77.4%) 32 (11.3%) 32 (11.3%) 1 - -
6. Rotterdam Study III-replication 129 (80.1%) 23 (14.3%) 9 (5.6%) - - -
Table 4.1 Age-related macular degeneration (AMD) staging results from six case-control datasets  
 AMD stage total data set AMD stage G119R carriers
2 3 4
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indistinct drusen (≥ 63 µm) only or pigmentary irregularities only) were excluded to 
avoid ambiguous diagnoses.
EUGENDA. Subjects were recruited through the ongoing EUGENDA study 
protocol.22,23 All subjects in the current study were unrelated, self-described 
Caucasian individuals from the Nijmegen (the Netherlands) or Cologne (Germany) 
area. All EUGENDA cases were ≥ 50 years of age, and the control subjects were ≥ 
65 years of age. 
Rotterdam Study I, II and III. Collections were derived from the three population-
based Rotterdam Studies.2,24 In the current study, only cases ≥ 50 years of age and 
control subjects ≥ 65 years old were included. Ninety-eight percent of individuals in 
the Rotterdam Studies were self-reported Caucasians.
Baltimore. Unrelated subjects were recruited at Johns Hopkins Hospital in Baltimore, 
Maryland, USA, as previously described.3,25,26 The subjects were self-described 
Caucasian individuals of European descent from the Baltimore replication collection. 
Genotyping
The genotyping in the present study was performed in primary and replication stages. 
In the primary stage, a panel of 84 cases (from the “EUGENDA-discovery” data set) 
was screened for CFI gene variants by polymerase chain reaction (PCR) amplification 
of all 13 coding exons and splice junctions. The primers and PCR conditions used to 
screen CFI are listed in Table 4.2.
Direct sequencing of the PCR amplicons was performed using an automated 
sequencer (BigDye Terminator, version 3 on a 3730 DNA analyzer; Applied 
Biosystems). The sequences were assembled using ContigExpress (Vector NTI 
Advance, version 11.0). Each novel variant was validated by and independent PCR. 
The p.Gly188Ala variant was screened in three affected family members of the 
proband, 809 unrelated cases and 254 control individuals by restriction enzyme 
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Exon Primers (5'-3') Annealing temperature (°C) Expected length (bp)
TTTCAAAAGAATACCTGGAGTGG
TTGCTGACTATAGAGTGGCATTG
TTGAAGCCACCAGACAACAC
GGCAACCCCTGATTTGTTTAG
CGTAAAATGATTGCTTACTATTACTTG
TGATGCACATAGTTAATTTTCTTAGG
CCTGCTACAGTAGGGTTATAAATGC
AACGAGGCATCAATCATTTG
AGGATGTCATGCCACCACTC
AAGAAAAGTTTCAGAATCCCTGG
AAAACAGAAATAAGGTGCAATGG
GCTGGGTTATTACTAAAATGTGGTC
GGGAGGATAAGTTTTAAGGCAG
CACTGAAATTACAGCCTAAACCAG
TCCAGCCTGTCTTGTACTGG
TGCTTTATCATCTGCCACAATC
GCATTTACAAAATTCTGGGG
TGCTTCTCTCTGAGTGCTAGG
CACCCTTTCATAATCCCAATG
GGAGGAGATGTTTGATAGGGG
GTTAAATGCCATGGAGGAGG
GGCATAAACTCTGTGGAGACC
Table 4.2 Complement factor I (CFI): primers and PCR conditions used.
1 59 263
2 60 573
3 58 431
4 59 339
5 and 6 60 489
7 59 258
8 58 208
9 and 10 59 585
13 59 446
11 57 504
12 59 266
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analysis using MnlI. In addition, we sequenced all coding exons of the CFH gene in 
the EUGENDA-discovery cohort (Table 4.3).
In the second (replication) stage, the frequency of the CFI p.Gly119Arg variant was 
measured by genotyping five replication cohorts (EUGENDA, Rotterdam Study I, 
Rotterdam Study II, Rotterdam Study III and Baltimore) using a custom-made TaqMan 
Variant rs-number Exon Patient number Population allele frequency*
c.2850G>T;p.Q950H rs149474608 19 #32 0.006
c.3628C>T;R1210C rs121913059 23 #19 0.0002
Table 4.3 Rare, non-synonymous CFH gene variants in the EUGENDA-discovery cohort
*Exome variant server database, European samples
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assay (Applied Biosystems). This assay consisted of two primers and two fluorescently 
labeled probes (Table 4.4). Genotyping was performed in a volume of 5 µl containing 
10 ng of genomic DNA according to the manufacturer’s recommendations 2.5 µl of 
2x Taqman Mastermix (Applied Biosystems), 0.0625 µl of the Taqman assay (40x) and 
1.44 µl of water. Genotyping was performed on a 7500 Fast Real-Time PCR System 
(Applied Biosystems) under the following conditions: pre-denaturing at 94°C for 12 
minutes, followed by 40 cycles of a denaturation step at 94°C for 15 seconds and 
an annealing/extension step at 60°C for 60 seconds. Genotypes were scored using 
the algorithm and software supplied by the manufacturer (Applied Biosystems). 
Eight wildtype controls and 24 positive p.Gly119Arg samples were included in each 
real-time PCR run and were 100% concordant, confirming the reproducibility of 
the Taqman assay. Samples identified as carriers by this assay were confirmed by 
independent PCR and sequencing. 
Haplotype analysis was performed in carriers of the p.Gly119Arg and p.Gly188Ala 
variants using selected SNPs spanning the CFI, PLAG12A and CCDC109B genes. 
SNPs were genotyped by PCR amplification and direct sequencing. Haplotypes 
were constructed using first-degree relatives of the cases.    
Proteins
C4BP27 and factor H (FH)28 were purified as described previously, and FH was purified 
further by affinity chromatography using a MRCOX24 (monoclonal anti-FH) column. 
Factor B, factor D, C3, C3b and C4b were purchased from Complement Technology. 
C3b and C4b were labeled with 125I (PerkinElmer) using iodination beads (Pierce). 
Factor I (FI) plasma concentration measurements
The concentration of FI in the plasma samples was measured by ELISA.29 Maxisorp 
Nunc Immunoplates (Nunc) were coated with rabbit anti-human FI Ig (generated 
in-house) in 50 mM sodium carbonate (pH 9.6) at 4°C overnight. Recombinant wt 
FI was used as a standard, and FI was detected using goat anti-human FI (Quidel) 
followed by rabbit anti-goat Ig conjugated with horseradish peroxidase (Dako); 
1,2-phenylenediamine dihydrochloride (Dako) was used as the substrate. The 
experiment was performed three times.
FAM-CTCTGAATCTGTATTTCTATG
Table 4.4. Primers and probes used for the CFI p.Gly119Arg Taqman-assay
Primers
forward: 5’- GCTACATATTGCACATTATTTTGTTTTTTTATTTTAGGA -3’
reverse:  5’- TCTTGGTCCACAAGTTTTACTTCAACT -3’
Probes
VIC-CTCTGAATCTGTATTTCCATG
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CFI cDNA cloning and mutagenesis
cDNA encoding the histidine-tagged full-length human FI was cloned into the 
eukaryotic expression vector pcDNA3 (Invitrogen).29 The mutations identified 
in the AMD patients were introduced using the QuikChange Lightning Site-
directed Mutagenesis Kit (Agilent Technologies) with the following primers for 
p.Gly119Arg: 5’- GTTTCCTTGAAGCATAGAAATACAGATTCAG -3’ and G188A: 5’- 
GTGCATTGCCGAGCATTAGAGACCAG -3’ and complementary reverse primers. 
The variants are underlined in the primer sequences. The variants were confirmed by 
automated DNA sequencing using the Big Dye terminator kit v3.1 cycle sequencing 
kit (Applied Biosystems). 
Expression of wt and mutant factor I (FI) 
HEK293 cells (ATCC number 1573-CRL) were transiently transfected with wt FI, one 
of the two mutant constructs or empty vector (pcDNA3) using Lipofectamine 2000, 
according to the manufacturer’s instructions (Invitrogen). Six hours after transfection, 
the transfection medium was replaced with Dulbecco’s modified Eagle’s medium 
with high glucose (Hyclone) and 10% fetal bovine serum (Invitrogen). Two days 
after transfection, the medium was replaced with serum-free Opti-MEM Glutamax 
(Invitrogen), and the cells were cultured for an additional three days. After collecting 
the conditioned medium, the cells were washed in ice-cold Dulbecco’s phosphate-
buffered saline (Hyclone) and lysed in ice-cold solubilization buffer containing 1% 
Triton X-100, 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1% aprotinin 
and 2 mM phenylmethanesulfonyl fluoride. The supernatants and cell lysates were 
analyzed by ELISA. The complete experiment was performed three times.
Purification of recombinant factor I (FI)
Wildtype and p.Gly119Arg FI were expressed in HEK293 cells in a stable manner 
and purified by affinity chromatography using nickel-nitrilotriacetic acid Superflow 
resin (Qiagen) as described previously.18 All proteins were stored at -80°C. Protein 
concentrations were determined by measuring the absorbance at 280 nm and 
subtracting the absorbance at 320 nm. The concentrations were then verified by 
SDS-PAGE followed by Coomassie staining of the gel.
Degradation of C3b and C4b in the fluid phase and C3b degradation on the cell 
surface
To study how the CFI variants would affect the protein’s ability to degrade C3b in the 
fluid phase, plasma samples were obtained from 97 healthy controls, 15 cases with a 
heterozygous p.Gly119Arg variant and four cases with a heterozygous p.Gly188Ala 
variant and diluted 30x in 50 mM Tris-HCl, 150 mM NaCl, pH 8.0 and mixed with 
trace amounts of 125I-labeled C3b. A mixture of recombinant FI (20 μg/ml), 20 μg/
ml plasma purified FH, 150 μg/ml C3b and 125I-labeled C3b was used as a positive 
control, and 125I-labeled C3b was used as a negative control. For recombinant wt 
86
chapter four
and mutant FI 1, 2.5 or 5 μg/ml was mixed with 20 μg/ml FH, 150 μg/ml C3b and 
125I-labeled C3b or 100 μg/ml C4BP, 50 μg/ml C4b and 125I-labeled C4b. A mixture 
of 20 μg/ml FI, 100 μg/ml C4BP, 50 μg/ml C4b and 125I-labeled C4b was used as a 
positive control for C4b degradation, and 125I-labeled C4b was used as a negative 
control. The samples were incubated at 37°C for 90 minutes, and the reaction was 
terminated by adding reducing sample buffer and boiling for three minutes. The 
proteins were separated on a 10-15% gradient SDS-PAGE gel and visualized using a 
Phosphoimager (GE Healthcare). The intensities of C3b and C4b and the 43-kDa and 
C4d cleavage products were analyzed using the ImageGauge software (Fujifilm). 
Each experiment was performed three times. The degradation of C3b in the plasma 
samples was calculated as the ratio between the 43-kDa product and the α’ chain; 
this ratio was normalized to the ratio of normal human serum to compare the results 
across different gels.
The ability of the CFI mutants to degrade C3b, deposited on the surface of 
erythrocytes, was also tested, essentially as described previously.28 Serum samples 
were obtained from 10 patients with the heterozygous G119R mutation, two with 
the heterozygous G188A mutation and 17 AMD patients without any CFI mutation. 
Sheep erythrocytes were coated with C3b, followed by incubation with 0.5% serum, 
diluted in TBS supplemented with 10 mM EDTA, for 1 h incubation at 37°C. To 
control the amount of deposited C3b on the erythrocytes as well as generated iC3b, 
the cells were incubated with specific monoclonal antibodies directed against either 
C3d (Quidel), which recognizes C3b or the degradation product iC3b (Quidel) and a 
ratio between these two was calculated.
Modeling of factor I (FI) and structural analysis of the mutations
The ternary complex was modeled using the human FI crystal structure (PDB entry 
2XRC) according to the procedure described by Roversi et al.30 All figures were 
generated using the YASARA program.31
Zebrafish analyses
A morpholino (MO) against zebrafish FI (12ng) was obtained from Gene Tools. 
eGFP:Fli1 transgenic zebrafish embryos were injected at the one- to two-cell stage 
with 1nl of solution. Overexpression of both 119Gly and 119Arg as well as rescues 
were performed by either injecting the corresponding human wildtype mRNA 
(100pg) alone and coinjecting with MO. mRNA was transcribed in vitro using SP6 
Message Machine Kit (Ambion). At 24hpf, zebrafish were grown in 1-Phenyl-2-
Thiourea (PTU) to prevent pigmentation. Zebrafish were collected and observed at 5 
days post fertilization. Vasculature was observed using the Nikon AZ100 Microscope 
with a using a 5.0-megapixel DS-Fi1 color digital camera head. Software to take 
measurements of the vessel diameter was NIS Elements AR 3.2. 
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Assessing renal function
The creatinine, urea nitrogen, and albumin concentrations were measured in stored 
serum obtained from ten cases carrying the p.Gly119Arg variant and 20 cases without 
the p.Gly119Arg variant (EUGENDA) using the ARCHITECT c16000 system (Abbott 
Diagnostics). Variant carriers and non-carriers were matched with respect to gender, 
age, and AMD stage for each eye. We calculated the estimated glomerular filtration 
rate (eGFR) using the MDRD equation as described previously32 and compared the 
eGFR of p.Gly119Arg cases to matched cases using an independent-samples Mann-
Whitney test.
Statistical analysis
Except where indicated otherwise, differences between the mutant and wildtype 
groups were analyzed using the one-tailed Fisher’s exact test. Differences with a 
P-value of < 0.05 were considered statistically significant. The data were analyzed 
using SPSS software, version 18.0 (SPSS, Chicago, IL).
Results
We sequenced all CFI coding exons from genomic DNA of 84 unrelated cases with 
AMD (“EUGENDA-discovery” data set), and found two heterozygous variants in 
four cases (Table 4.5). Three cases carry the p.Gly119Arg substitution; the fourth 
case carries the p.Gly188Ala substitution. Neither of these variants was identified 
in 192 ethnicity- and age-matched controls. The p.Gly188Ala substitution was also 
detected in three affected family members of the proband, although it was not found 
in 809 unrelated AMD cases. No co-existing mutations in the complement factor H 
(CFH) gene were identified in cases carrying the CFI p.Gly119Arg or p.Gly188Ala 
substitutions (Table 4.3). Haplotype analysis revealed that the p.Gly119Arg and 
p.Gly188Ala variants reside on different haplotypes (Figure 4.1).
Variant rs-number Exon Patient number Population allele frequency*
c.355G>A;p.G119R rs141853578 3 #8, #47, #69 0.001
c.482+6C>T rs79375065 3 #71 0.003
c.482+21A>G - 3 #3 -
c.563G>C;p.G188A - 4 #73 -
c.1429+33A>G rs9998151 11 #11 0.042
c.1534+5G>T rs114013791 12 #21, #29 0.015
Table 4.5. CFI gene variants in the EUGENDA-discovery cohort
*Exome variant server database, European samples
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The p.Gly119Arg variant was studied in 1,014 AMD cases and 711 controls 
(“EUGENDA-replication” data set). The variant was identified in eleven additional 
cases, but was absent from controls, demonstrating a strong association between 
AMD and p.Gly119Arg (P = 2.16 x 10-4, Table 4.6). In addition, we genotyped 2,469 
cases (1,754 European and 715 US) and 3,035 controls (2,883 European and 152 US) 
from four independent studies (Table 4.6). In this replication cohort, the p.Gly119Arg 
variant was identified in six cases and one control (P=0.035). Notably, this 73-year-old 
control individual had numerous hard drusen in all four quadrants of the peripheral 
retina but with a normal macula. In total, we identified the p.Gly119Arg variant in 
20 of 3,567 cases versus only one of 3,937 controls, consistent with p.Gly119Arg 
conferring a high risk for developing AMD (P = 3.79 x 10-6, odds ratio = 22.20; 95% 
#73 #8 #47 #69
Figure 4.1. Haplotypes of SNPs surrounding the CFI gene in one case carrying the p.Gly188Ala variant 
(#73) and three unrelated cases carrying the p.Gly119Arg variant (#8, #47, #69). Haplotypes were 
constructed using first-degree relatives. The p.Gly119Arg and p.Gly188Ala variants reside on different 
haplotypes. A 140-kb shared haplotype spanning the CFI gene (extending from SNP rs13117504 to 
SNP rs7675460) was observed in three cases carrying the p.Gly119Arg variant.
Fisher's Exact
AMD Unaffected AMD Unaffected One-tailed P value
1. EUGENDA-discovery 3 0 81 192
2. EUGENDA-replication 11 0 1,003 711
3. Baltimore-replication 2 0 713 152
4. Rotterdam Study I-replication 3 0 1,307 1,767
5. Rotterdam Study II-replication 1 1 282 617
6. Rotterdam Study III-replication 0 0 161 498
     Meta-analysis (1+2+3+4+5+6) - - - - 3.79x10-6
0.035
Table 4.6 CFI genotyping results of the p.Gly119Arg variant in individuals of six case-control data sets
G119R heterozygotes G119 homozygotes
2.16x10-4
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confidence interval 2.98-164.49). Of note, the frequency of the p.Gly119Arg variant 
differed among the independent cohorts (Table 4.6). An explanation may lie in the 
difference in distribution of AMD stages in the EUGENDA and Baltimore cohorts 
(mainly stage 4) compared to the Rotterdam Studies (mainly stage 2). Since most 
carriers of the p.Gly119Arg variant have AMD stage 4 (Table 4.1), this may explain 
the lower frequency observed in the Rotterdam Studies. 
The p.Gly119Arg and p.Gly188Ala variants affect highly conserved glycine residues 
in the CD5 domain of FI and are predicted to alter the packing and stability of this 
domain (Figure 4.2).16,35 To investigate the consequences of the AMD-associated 
variants on protein expression and function, we measured the concentration of FI 
and the degradation of C3b in plasma and serum samples. Plasma FI levels were 
measured in 15 cases carrying p.Gly119Arg, four cases carrying p.Gly188Ala, 97 
age-matched controls and 100 cases without a CFI mutation. The cases carrying the 
p.Gly119Arg variant had lower plasma FI levels compared to both controls and cases 
without a CFI variant (P = 2.08 x 10-8 and P = 1.69 x 10-3, respectively, two-tailed Kruskal-
Wallis with Dunn’s post-hoc test; Figure 4.3A). We observed similar differences for 
the p.Gly188Ala allele (P = 4.74 x 10-3 and P = 4.74 x 10-3 , respectively; Figure 4.3A). 
Plasma samples of cases carrying the p.Gly119Arg or p.Gly188Ala variants had a 
lower capacity to degrade 125I-labeled C3b in the fluid phase compared to controls 
(P = 8.04 x 10-4 and P = 0.029, respectively, two-tailed Kruskal-Wallis with Dunn’s 
post-hoc test; Figure 4.3B,C). Serum samples of cases carrying the p.Gly119Arg 
variant had a lower ability to degrade C3b on the cell surface, compared to cases 
without a CFI mutation (P = 5.43x10-4, two-tailed Kruskal-Wallis with Dunn’s post-hoc 
test; Figure 4.3D).  
To interrogate further the consequences of the p.Gly119Arg and p.Gly188Ala 
variants on the functional activity of FI, we expressed wt and mutant FI proteins in 
HEK293 cells. Both p.Gly119Arg and p.Gly188Ala were expressed and secreted at 
lower levels than wt FI (P = 8.45 x 10-4 and P = 2.81 x 10-4, respectively, two-tailed 
one-way ANOVA with Dunnett’s post-hoc test; Figure 4.4A). The small amounts of 
expressed p.Gly119Arg FI were purified and tested for the ability to cleave C3b and 
C4b (expression of the p.Gly188Ala variant was too low for the protein to be purified). 
At 5 µg/ml, the purified p.Gly119Arg FI degraded both C3b and C4b at modest, 
yet significantly higher efficiency than wt FI (Figure 4.4B-E, P = 1.19 x 10-2 and P = 
3.13 x 10-3, respectively, two-tailed two-way ANOVA with Bonferroni post-hoc test). 
However, the severely impaired expression and secretion of the mutant protein led 
to a net effect (-17%) of significantly decreased C3b degradation (Figure 4.3).
Taken together, our in vitro data, as well as measurements from plasma samples and 
serum samples, pointed to a model in which the 119Arg-variant confers a lower FI 
activity compared to 119Gly. Next, we sought to test this model in vivo. It has been 
shown previously that genetic manipulation of known AMD loci in zebrafish embryos 
results in vascular or angiogenic perturbations; these can be monitored with the 
fli1-EGFP transgenic reporter, in which EGFP is expressed specifically in the vascular 
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Figure 4.2. Schematic and 
structural view of factor I (FI). 
(A,B) The CFI gene contains 13 
exons and the exons correspond 
well to the domain structure. (C) 
FI is composed of the following 
domains: FI membrane attack 
complex domain (FIMAC), a 
CD5-like domain, two low-density 
lipoprotein receptor 1 and 2 
(LDLR1 and 2), and the serine 
protease (SP) domain. (D) Model 
of the ternary complex containing 
C3b, factor H (FH) and FI. A surface 
representation of C3b is shown in 
gray; the surface representation 
of the four FH domains (FH1-4) 
is shown in red. FI is shown as a 
ribbon style cartoon. The CD5 
domain is shown in green, the 
FIMAC and LDLR domains are 
shown in blue, and the catalytic 
SP domain is shown in orange. 
(E) The Gly119 residue is located 
at the surface of the CD5 domain 
and is not involved in any inter-
domain contacts. However, the 
surface loop containing Gly119 
links the preceding FIMAC to the 
CD5 domain and therefore packs 
against the CD5 domain. The 
introduction of a much larger and 
charged arginine residue in the 
p.Gly119Arg variant is predicted 
to disturb this packing and thus 
destabilize the CD5 domain. (F) 
The Gly188 residue is located 
at the interface of the CD5 
domain and the LDLR domains. 
Glycine-188 is important for the 
required structure of the loop, 
which mediates many inter-
domain contacts in the overall FI 
structure and does not tolerate 
substitution by any other amino 
acids.33,34 Introduction of any 
other side chain at this position 
(such as an alanine or valine 
introduced by the p.Gly188Ala 
and p.Gly188Val variants18) will 
perturb the orientation of the 
loop and disrupt inter-domain 
packing within the heavy chain.
A
B
C
D
E F
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Figure 4.3. Factor I (FI) concentrations and degradation of C3b in plasma/serum of cases carrying 
the p.Gly119Arg or p.Gly188Ala variant, cases without a CFI variant and ethnicity- and age-matched 
controls. (A) FI concentration was measured by ELISA in plasma samples of 15 cases carrying 
p.Gly119Arg, four cases carrying p.Gly188Ala, 97 ethnicity- and age-matched control individuals and 
100 cases without a CFI variant. The median FI concentration, shown as a horizontal line, is significantly 
lower in cases carrying the p.Gly119Arg variant and the p.Gly188Ala variant compared to cases without 
a CFI variant or controls. (B) Serum samples of 10 cases carrying p.Gly119Arg, two cases carrying 
p.Gly188Ala and 17 cases without a CFI variant were tested for their ability to degrade C3b deposited on 
the surface of sheep erythrocytes. The experiment was performed three times and the ratio between the 
generated iC3b and the deposited C3d (i.e. C3b) was calculated (the median is shown as a horizontal 
line). (C) Plasma samples of 15 cases carrying p.Gly119Arg, four cases carrying p.Gly188Ala and 97 
controls (Ctrls) were incubated with trace amounts of 125I-labeled C3b for 90 minutes at 37°C and then 
separated on a 10-15% gradient SDS-PAGE gel. 125I-labeled C3b was loaded as negative control (-), and 
a mixture of 20 μg/ml recombinant FI, 20 μg/ml plasma purified factor H, 150 μg/ml C3b and 125I-labeled 
C3b was used as a positive control (+). (D) The ratio between the 43-kDa degradation product and the 
α’ band is plotted for cases carrying the p.Gly119Arg or p.Gly188Ala variant, and controls. The ratio was 
normalized to pooled normal human serum (NHS) to facilitate comparison of the individual gels. The 
experiment was performed three times, and the median is shown as a horizontal line.
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Figure 4.4. Expression of recombinant factor I (FI) in HEK293 cells, and degradation of C3b and C4b 
by recombinant wt and mutant p.Gly119Arg FI. (A) HEK293 cells were transiently transfected with 
empty vector (pcDNA3) or a plasmid expressing wildtype (wt), p.Gly119Arg or p.Gly188Ala FI. The FI 
concentrations in the supernatants and cell lysates were measured by ELISA and the ratios between the 
concentrations of FI in the supernatants and cell lysates are plotted. The experiment was performed 
three times, and the results are presented as mean ± standard deviation (SD). (B, C) Recombinant wt 
or p.Gly119Arg FI (1, 2.5 or 5 μg/ml) was incubated with C3b and factor H (FH) or (D, E) C4b and C4BP 
with trace amounts of 125I-labeled C3b/C4b for 90 minutes at 37°C and then separated on a 10-15% 
gradient SDS-PAGE gel. 125I-labeled C3b was loaded as negative control (-), and a mixture of 20 μg/ml 
recombinant FI, FH/C4BP, C3b/C4b and 125I-labeled C3b/C4b was used as a positive control (+). The 
ratio between the 43-kDa and C4d products and the α’ bands are plotted in (C) and (E). The experiment 
was performed three times, and mean ± SD is plotted. ns; non significant.
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endothelium.36 For example, suppression of vascular endothelial growth factor A 
(VEGF-A) causes severe loss of vasculature throughout the organism,37 recapitulating 
the mouse phenotype.38 Similarly, suppression of the AMD candidate PLD1 results in 
loss of intersegmental vessels of the truncal vasculature.39 Given these observations, 
we asked whether expression of 119Gly- or 119Arg-encoding human CFI mRNA 
might have a differential effect on vascular architecture. Injection of 100 pg of 119Gly-
encoding, capped human mRNA into 2-4 cell stage fli-EGFP embryos followed by 
scoring at five days revealed defects in the morphology of the hyeloid vessels in the 
developing retina; objective scoring (masked to injection cocktail) of the diameter 
of these vessels at three different branch positions in a field anchored in the central 
retina (n = 40-60 embryos per injection, optic nerve positioned always at bottom 
center of the field) showed reduction of tube thickness compared to dye-injected 
embryos (P < 0.0001, two-tailed student t-test; Figure 4.5). By contrast, embryos 
injected with 100 pg of human mRNA encoding the 119Arg allele were overall 
indistinguishable from controls; although occasional embryos showed structural 
defects of the hyaloid vessels, the average thickness was indistinguishable from 
sham (n = 40-60 embryos; Figure 4.5). Further, suppression of CFI with a morpholino 
(MO) against the acceptor site of exon 3 of the sole CFI zebrafish locus induced 
similar retinal pathology, albeit less severe compared to mRNA overexpression (P < 
0.0001, two-tailed student t-test), which could be ameliorated by 100 pg of wt mRNA. 
Notably, MO suppression or overexpression of human CFI mRNAs did not induce 
abnormal phenotypes in the truncal vasculature (Figure 4.5) or any appreciable 
gross dysmorphology, intimating a specific effect in the retina and supporting the 
specificity of the observed phenotypes. Taken together, these data are consistent 
with the data derived from both patient sera and in vitro studies that the p.Gly119Arg 
variant reduces the activity of FI and also suggest that CFI might be dosage-sensitive 
in either direction (too much or too little).
The p.Gly119Arg variant was described previously in several individuals with aHUS,17,40 
hinting at a direct link between AMD and aHUS in a fashion similar to recent reports 
for CFH.12 We assessed renal function in p.Gly119Arg AMD cases; we measured 
the estimated glomerular filtration rate (eGFR; normal > 90 ml/min/1.73m2) using 
serum creatinine, urea nitrogen, and albumin measurements of ten cases. None of 
these cases had clinically significant renal dysfunction (defined as eGFR < 30 ml/
min/1.73m2); however, a mild subclinical decrease in renal function was noted (median 
eGFR of 81 ml/min/1.73m2). Because AMD patients generally have subclinical renal 
dysfunction,41 we compared the renal function of these p.Gly119Arg cases to that of 
20 cases who were matched for age, gender and disease severity but did not carry 
the p.Gly119Arg variant. No significant difference was observed (P = 0.860; two-
tailed Mann-Whitney test). In addition, none of the cases carrying the p.Gly119Arg 
variant had malignant hypertension, pulmonary edema, thrombocytopenia or 
anemia, features that were observed previously in aHUS patients carrying the 
p.Gly119Arg variant.42 This suggests that the p.Gly119Arg variant is not sufficient and 
that additional factors — such as a second variant or external trigger — are required 
to develop aHUS.
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Figure 4.5. In vivo analysis of the p.Gly119Arg variant. (A) Representative images of the retinal 
vasculature in 5dpf Fli1:EGFP zebrafish injected with a variety of cocktails; the optic nerve is at the root 
of the illustrated vascular tree. Magnification 8x. (B) Comparison of averaged hyaloid vessel diameter 
across several genetic manipulations (averaged three measurements per image across 40-60 embryos); 
average vessel diameter of CFI MO, 119Gly hsmRNA, and 119Gly hsmRNA + CFI MO injected zebrafish 
were significantly different than controls (P < 0.0001). Error bars represent the Standard Error. (C) 
Distribution of hyaloid vessel diameter sizes of control vs 119Gly and 119Arg. (D) Truncal vasculature 
illustrating no appreciable phenotypic differences to control. 
Discussion
Here we report that rare, highly penetrant CFI variants that reduce the expression 
and secretion of FI can cause AMD. These data represent the first direct evidence 
that FI deficiency confers a high risk of developing AMD and increase support for 
the hypothesis that the previously observed association between AMD and SNPs 
near the CFI gene are driven by CFI rather than the downstream genes PLAG12A or 
CCDC109B.20 However, further research is needed to explain the functional effect of 
the associated SNPs or an unidentified variant tagged by these SNPs.20 In the context 
of our findings, it is plausible that these SNPs might be associated with altered FI 
expression levels, since our in vitro data indicate a loss of function mechanism, while 
our zebrafish studies, with the caveat that caution must be exercised in interpreting 
data from a developmental system for an adult-onset disorder, suggest a “goldilocks 
effect” in which dosage perturbations at either end of the spectrum can be 
deleterious to retinal vasculature. A functional link between FI dysfunction and AMD 
pathogenesis was proposed recently.19 FI is constitutively expressed by the retinal 
pigment epithelium (RPE), the site of drusen formation in AMD. Amyloid-β, a main 
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constituent of drusen, binds to FI, which inhibits the ability of FI to cleave C3b to 
inactivated iC3b. In addition, exposure of RPE cells to amyloid-β decreases secretion 
of FI. This supports a central role of impaired FI function in deregulated complement 
activation in AMD.
Our findings have implications for both predictive testing and for the development 
of new AMD treatments. The first prognostic AMD tests, which are based on a small 
number of common variants, are currently being marketed. However, these tests are 
not reliable for individuals carrying rare variants that confer a high risk of developing 
AMD. It is therefore essential to understand the role of these rare variants in AMD 
before reliable genetic tests can be developed. These tests should not only be 
based on a small number of common variants, but will also need to address rare, 
highly penetrant variants, particularly in the case of densely affected families.43
Finally, new treatments are currently being developed to selectively inhibit 
complement activation in AMD. However, recent phase 2 clinical trials using 
eculizumab, an inhibitor of complement component C5, appeared not to effectively 
restrict geographic atrophy or drusen area in AMD patients.44,45 Complement 
inhibitors are likely to be more effective for individuals carrying rare variants that 
severely affect complement activation. Future research is warranted to unravel 
pathogenic mechanisms in various subgroups of AMD, and to develop personalized 
treatments tailored to the patient’s individual genetic makeup. 
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Objectives: To determine if small hard drusen in patients with cuticular drusen (CD) 
show short-term changes.
Methods: Ten subjects with CD were longitudinally followed during a period of 4 
months by spectral-domain optical coherence tomography. Drusen that showed a 
spontaneous change in volume were further analyzed according to 5 morphologic 
parameters: shape, reflectivity, homogeneity, and concurring photoreceptor layer/
retinal pigment epithelium damage. Odds ratios (OR) and risk for regression and 
progression of drusen volumes were calculated.
Results: One hundred and five small hard drusen in 19 eyes showed a spontaneous 
change in volume over the period of follow-up. Drusen with a “pointed” shape 
were significantly associated (P = 0.031; OR 4.89; 95% confidence interval [CI] 1.16-
20.67) with spontaneous progression in drusen volume, with a chance of 0.80 (95% 
CI 0.55-0.93) to progress. Drusen that showed a decreased reflectivity of overlying 
photoreceptor layer (P = 0.041; OR 7.67; 95% CI 1.09-54.24) or retinal pigment 
epithelium (P = 0.022; OR 12.38; 95% CI 1.44-106.57), showed a significant association 
with spontaneous regression in drusen volume, with chances of regression of 0.86 
(95% CI 0.41-0.98) and 0.89 (95% CI 0.49-0.99), respectively.
Conclusions: Small hard drusen in patients with the CD phenotype are subject to 
a process of short-term remodeling. The dynamic nature of this disease points to 
high biochemical activity that may be sensitive to future pharmacologic treatment 
strategies. In addition, these short-term changes of drusen may be a source of 
misclassification in disease staging.
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Introduction
Macular drusen are the hallmark lesions of age-related macular degeneration 
(AMD).1,2 They are identified on ophthalmoscopy as focal yellow-white subretinal 
deposits, which are pathologic extracellular deposits between the basal lamina 
of the retinal pigment epithelium (RPE) and the inner collagenous layer of Bruch’s 
membrane.3–5 Drusen contain a wide variety of compounds that appear to reflect the 
complex pathogenesis of AMD. Important constituents of drusen are neutral lipids,6,7 
carbohydrates,8 zinc,9 and a wide variety of proteins. Many proteins found in drusen 
are associated with inflammation and/or immune-associated processes, including a 
broad spectrum of complement components.10,11 In addition, associations between 
AMD and genetic variants in complement genes have been reported, which supports 
the role of low-grade inflammation and an abnormal regulation of the complement 
system in drusen pathogenesis.12–20 Drusen are an important quantifier of the severity 
of AMD. Therefore, the size and number of drusen are used for AMD staging and for 
the prediction of the likelihood of disease progression and vision loss.1,2,21 
Different clinical subtypes of drusen have been described in AMD, but all drusen 
seem to be indistinguishable in location, composition, and substructure.5 “Cuticular 
drusen (CD),” also termed “basal laminar drusen,” refers to an early-onset drusen 
phenotype with innumerable small (25 to 75 µm) hard drusen.22,23 This subtype of 
AMD is more easily visualized angiographically than biomicroscopically, with a typical 
“stars-in-the-sky” appearance during the early arteriovenous phase of fluorescein 
angiography (Figure 5.1).24 In later stages, the number of drusen often increases, 
with clustered groups of drusen scattered throughout the retina.22
Figure 5.1. Fluorescein angiographic photograph of the left 
eye of a 45-year-old patient with cuticular drusen.
short-term chanGes of cuticular drusen
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In general, color fundus photographs are used to evaluate the morphology of 
drusen over time. However, color images do not provide detailed information 
about the changing morphology of small drusen.25–27 The introduction of spectral-
domain optical coherence tomography (SD-OCT) has enabled an improved in vivo 
visualization of drusen morphology.28 SD-OCT is able to acquire 3-dimensional 
images of the retina with high speed and high resolution. Subsequently, studies of 
the fine details of small drusen and adjacent retinal structures become possible.28,29
After we observed occasional changes of drusen morphology in routinely followed 
eyes with CD, we decided to longitudinally investigate the appearance of small hard 
drusen in eyes with this phenotype. The focus of our investigation was to determine 
whether morphologic parameters may be predictive for processes of progression or 
regression of small hard drusen in CD affected eyes.
Methods
Patients
A total of 10 subjects who met the diagnostic criteria of CD were retrieved from the 
European Genetic Database (EUGENDA, www.eugenda.org), a large multicenter 
database for clinical and molecular analysis of AMD and different early-onset drusen 
phenotypes. 
For inclusion in the study, subjects had CD of the posterior pole and ocular media 
allowing adequate SD-OCT scanning, defined by a maximum score of NO3/NC2/
C1/P1 according the Lens Opacities Classification System III.30 Study participants 
had to be able to fixate for at least 1 minute per eye to allow adequate SD-OCT 
scanning. The CD phenotype was defined as a symmetrically distributed pattern 
between both eyes of at least 50 scattered, uniformly sized, small (25 µm to 75 µm), 
hyperfluorescent drusen on fluorescein angiography in each eye, of which at least 
20 drusen are located outside the Wisconsin age-related maculopathy grading 
template.31 Eyes with choroidal neovascularization (CNV), a large area of central 
geographic atrophy (> 1500 µm), and retinal abnormalities other than AMD-related 
were excluded from the study. In order to exclude possible effects of antioxidant 
agent use on changing drusen morphology, the use of antioxidant agents was 
prohibited 1 month prior to study entry and during the follow-up period.
Image aquisition
All study participants were examined 3 times with a 2-month interval during a 
follow-up period of 4 months. During each visit, visual acuity was recorded with 
Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Multimodal imaging 
was performed by a combined confocal scanning laser ophthalmoscope (cSLO)/
SD-OCT device (SPECTRALIS; Heidelberg Engineering, Heidelberg, Germany) 
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after pupil dilation with 1 drop of 2.5% phenylephrine hydrochloride and 1 drop 
of 1% tropicamide. A standardized imaging protocol was performed in each study 
eye, which included near-infrared reflectance imaging in high-speed mode (λ = 815 
nm; scan angle, 30 degrees; image resolution, 768 x 768 pixels) and simultaneous 
SD-OCT scanning (λ = 870 nm; 40 000 A-scans per second; number of B-scans, 38; 
distance between B-scans, 122 µm) using a second, independent pair of scanning 
mirrors. Because of the independent pairs of scanning mirrors, eye movements 
were registered and corrected automatically (“eye tracking”) by the cSLO/SD-OCT 
device. The eye tracker enabled the identification of the same scanning location 
during follow-up visits. By this means, a very high repeatability and reproducibility 
of longitudinal measurements with an exceedingly small measurable change (1.5 
µm) of retinal structure has been shown for this device.32 Therefore, a highly reliable 
comparison of drusen as small as 25 to 75 µm, like in cuticular drusen, is possible on 
follow-up OCT scans.
To increase image quality, the Automatic Real-Time (ART) function was used. With 
ART activated, 35 SD-OCT B-scans of the same scanning location were performed 
during the scanning process and images were averaged for noise reduction.
Image analysis
For the morphologic evaluation of the small hard drusen, baseline SD-OCT scans 
and SD-OCT scans after 4 months were studied side by side by 2 graders (J.vd.V. 
and Y.L.). Only drusen that showed increasing volume over time or decreasing 
volume over time were analyzed for this study (Figures 5.2 and 5.3). The analysis 
focused on 5 morphologic parameters (Figure 5.4), partly adopted from Khanifar 
and associates,33 with the additional parameters for photoreceptor layer and 
RPE layer damage, scored as follows: the shape of the drusen was characterized 
as dome-shaped (basal diameter ≥ height), pointed (basal diameter < height), or 
saw-toothed (grouped pointed drusen edging each other at the level of Bruch’s 
membrane); the predominant internal reflectivity between RPE elevation and the 
Bruch’s membrane was characterized as low (isoreflective or hyporeflective compared 
to the photoreceptor outer segment layer), medium (hyperreflective compared to 
the photoreceptor outer segment layer but hyporeflective relative to the RPE), or 
high (isoreflective or hyperreflective in relation to the RPE); the homogeneity of 
internal drusen reflectivity was characterized as homogeneous (uniform internal 
reflectivity), nonhomogeneous with core (varying internal reflectivity with a distinct 
single focus of hyperreflectivity), or nonhomogeneous without core (varying internal 
reflectivity without a distinct focus of hyperreflectivity); photoreceptor layer damage 
was characterized as present (hyporeflective photoreceptor layer overlying a druse 
relative to the average photoreceptor layer reflectivity in the surrounding areas 
without drusen) or absent (isoreflective photoreceptor layer overlying a druse 
relative to the surrounding average photoreceptor layer reflectivity); and RPE 
damage was characterized as present (hyporeflective RPE overlying a druse relative 
to the surrounding average RPE reflectivity in retinal areas without drusen) or absent 
(isoreflective RPE overlying a druse relative to surrounding average RPE reflectivity).
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Statistics
Statistical analysis was performed by SPSS statistical software, version 18.0 (SPSS 
Inc., Chicago, Illinois, USA). The prevalence (number of eyes and number of drusen) 
of each basic morphologic pattern was calculated and analyzed with descriptive 
statistics. Drusen were measured by the Heidelberg Eye Explorer software, version 
1.6.4.0 (Heidelberg Engineering GmbH, Heidelberg, Germany), and a ratio between 
height and basal diameter was calculated. For interindividual correction, a model 
for generalized estimating equations for binary outcome was used to analyze 
Figure 5.2. Drusen volume at regression in 
a patient with cuticular drusen recorded by 
spectral-domain optical coherence Tomography 
(SD-OCT). (A) Baseline: Homogeneous, 
domeshaped hard drusen (white arrow heads) 
without damage of the overlying retinal pigment 
epithelium or photoreceptor layer. (B) After 2 
months of follow-up. (C) After 4 months of follow-
up; note the total regression of the hard drusen 
(black arrow heads) without detectable changes 
on SD-OCT at the former areas of homogeneous, 
dome-shaped hard drusen.
A
B
C
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differences in drusen characteristics between drusen that showed a progression 
in drusen volume (the “drusen progression” group) and drusen that showed an 
decreasing drusen volume (the “drusen regression” group). Strength of association 
of the different drusen characteristics between the “drusen regression” group and 
“drusen progression” group is shown as odds ratios (ORs) with a 95% confidence 
interval (95% CI). The chance of drusen morphology change was expressed as a 
value between 0 (0% chance) and 1.0 (100% chance). Reported P values are 2-sided 
and a value of < 0.05 was considered statistically significant.
Figure 5.3. Druse showing volume progression 
in a patient with cuticular drusen recorded by 
spectral-domain optical coherence tomography 
(SD-OCT). (A) Baseline: A homogeneous, 
very small dome-shaped hard druse (white 
arrowhead) without overlying retinal pigment 
epithelium or photoreceptor layer damage. (B) 
After 2 months follow-up and (C) after 4 months 
follow-up: Progression towards a larger druse 
(black arrow head) is seen.
A
B
C
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Results
SD-OCT was performed on 19 eyes of 10 patients. One eye was excluded from 
this study because of a large area of central geographic atrophy. The mean age of 
the patients was 64.6 ± 13.9 years, ranging from 45 to 86 years. Nine patients were 
female and 1 patient was male. The mean baseline best-corrected visual acuity was 
78 letters (range, 20 to 95). In all eyes visual acuity remained stable (P = 0.231) during 
the period of follow-up, with a mean increase of 1 letter on the ETDRS visual acuity 
chart.
The morphologic results of small hard drusen with spontaneous volume regression 
and the morphologic results of small hard drusen with progression are depicted in 
the Table 5.1. The most common small hard drusen that showed short-term changes 
were homogeneous, dome-shaped drusen with medium internal reflectivity and 
without overlying RPE or photoreceptor layer damage. Dome-shaped small hard 
drusen (n = 67) showed an average base-to-height ratio of 1:0.58, while pointed small 
hard drusen (n = 25) showed an average base-to-height ratio of 1:1.43. Of the cases 
with drusen volume regression, 30.6% (15/49) completely regressed during follow-
up, whereas 69.4% (34/49) showed a decreased drusen volume only. In cases of small 
hard drusen with increased drusen volume, 33.9% (19/56) showed development of 
new drusen, whereas 66.1% (37/56) of those small hard drusen showed an increased 
drusen volume.
Pointed drusen showed a significant association with a progression in volume (P 
= 0.031; OR 4.89; 95% CI 1.16-20.67), with a chance of 0.80 (95% CI 0.55-0.93) for 
volume progression. No significant longitudinal changes were observed for dome-
shaped and saw-toothed drusen. Drusen with overlying photoreceptor layer or RPE 
damage showed  a  statistically significant association with a regression in volume 
A B DC E
Figure 5.4. Five of the combined morphologic drusen features seen in patients with cuticular 
drusen. (A) Dome-shaped, medium reflectivity, homogeneous, no retinal pigment epithelium (RPE) 
or photoreceptor layer damage. (B) Pointed, medium reflectivity, nonhomogeneous with core, no 
RPE or photoreceptor layer damage. (C) Saw-toothed, medium reflectivity, homogeneous, no RPE or 
photoreceptor layer damage. (D) Pointed, medium reflectivity, RPE and photoreceptor layer damage. (E) 
Dome-shaped, medium reflectivity, homogeneous, photoreceptor layer damage without RPE damage.
chapter five
107
short-term chanGes of cuticular drusen
N
o.
 D
ru
se
n 
(%
)
N
o.
 E
ye
s 
(%
)*
N
o.
 D
ru
se
n 
(%
)
N
o.
 E
ye
s 
(%
)*
Sh
ap
e
   
D
om
e
37
 (7
5.
5%
)
16
 (8
4.
2%
)
30
 (5
3.
6%
)
14
 (7
3.
7%
)
n.
s.
   
Po
in
te
d
  5
 (1
0.
2%
)
  3
 (1
5.
8%
)
20
 (3
5.
7%
)
10
 (5
2.
6%
)
0.
03
1
   
Sa
w
-t
oo
th
ed
  7
 (1
4.
3%
)
  5
 (2
6.
3%
)
  6
 (1
0.
7%
)
  6
 (3
1.
6%
)
n.
s.
Re
fle
ct
iv
ity
   
Lo
w
 (≤
 p
ho
to
re
ce
p
to
r l
ay
er
)
  2
 (4
.1
%
)
  2
 (1
0.
5%
)
  1
 (1
.8
%
)
  1
 (5
.3
%
)
n.
s.
   
M
ed
iu
m
 (b
et
w
ee
n 
p
ho
to
re
ce
p
to
r l
ay
er
 a
nd
 R
PE
)
47
 (9
5.
9%
)
18
 (9
4.
7%
)
55
 (9
8.
2%
)  
18
 (9
4.
7%
)
n.
s.
   
H
ig
h 
(≥
RP
E)
  0
 (0
.0
%
)
  0
 (0
.0
%
)
  0
 (0
.0
%
)
  0
 (0
.0
%
)
n.
s.
H
om
og
en
ei
ty
   
H
om
og
en
eo
us
43
 (8
7.
8%
)
19
 (1
00
.0
%
)
  5
1 
(9
1.
1%
)
  1
7 
(8
9.
5%
)
n.
s.
   
N
on
ho
m
og
en
eo
us
 w
ith
 c
or
e
  0
 (0
.0
%
)
  0
 (0
.0
%
)
  2
 (3
.6
%
)
   
 2
 (1
0.
5%
)
n.
s.
   
N
on
ho
m
og
en
eo
us
 w
ith
ou
t c
or
e
  6
 (1
2.
2%
)
  5
 (2
6.
3%
)
  3
 (5
.4
%
)
   
 3
 (1
5.
8%
)
n.
s.
Ph
ot
or
ec
ep
to
r l
ay
er
 d
am
ag
ed
   
Pr
es
en
t
  6
 (1
2.
2%
)
  4
 (2
1.
1%
)
  1
 (1
.8
%
)
  1
 (5
.3
%
)
0.
04
1
   
A
b
se
nt
43
 (8
7.
8%
)
18
 (9
4.
7%
)
55
 (9
8.
2%
)
18
 (9
4.
7%
)
RP
E 
d
am
ag
ed
   
Pr
es
en
t
  9
 (1
8.
2%
)
  6
 (3
1.
6%
)
  1
 (1
.8
%
)
  1
 (5
.3
%
)
0.
02
2
   
A
b
se
nt
40
 (8
3.
3%
)
17
 (8
9.
5%
)
55
 (9
8.
2%
)
18
 (9
4.
7%
)
A
b
b
re
va
tio
ns
: n
.s
., 
no
t s
ig
ni
fic
an
t; 
RP
E,
 re
tin
al
 p
ig
m
en
t e
p
ith
el
iu
m
.
* N
o.
 E
ye
s 
re
p
re
se
nt
s 
th
e 
to
ta
l n
um
b
er
 o
f e
ye
s 
ou
t o
f 1
9,
 h
ar
b
or
in
g
 d
ru
se
n 
w
ith
 s
p
ec
ifi
c 
m
or
p
ho
lo
g
ic
 p
ar
am
et
er
.
† P
 V
al
ue
 re
p
re
se
nt
s 
th
e 
d
iff
er
en
ce
 in
 a
ss
oc
ia
tio
n 
b
et
w
ee
n 
th
e 
d
ru
se
n 
re
g
re
ss
io
n 
g
ro
up
 a
nd
 th
e 
d
ru
se
n 
p
ro
g
re
ss
io
n 
g
ro
up
.
Ta
b
le
5.
1.
Su
m
m
ar
y
of
d
ru
se
n
p
at
te
rn
s
se
en
in
th
e
d
ru
se
n
re
g
re
ss
io
n
g
ro
up
an
d
th
e
d
ru
se
n
p
ro
g
re
ss
io
n
g
ro
up
,
or
g
an
iz
ed
b
y
b
as
ic
m
or
p
ho
lo
g
ic
p
ar
am
et
er
s
D
ru
se
n 
Re
g
re
ss
io
n 
G
ro
up
D
ru
se
n 
Pr
og
re
ss
io
n 
G
ro
up
P 
Va
lu
e†
108
chapter five
(P = 0.041; OR 7.67; 95% CI 1.09-54.24 and P = 0.022; OR 12.38; 95% CI 1.44-106.57), 
with similar chances for drusen volume regression (0.86 [95% CI 0.41-0.98] and 0.89 
[95% CI 0.49-0.99], respectively). Drusen reflectivity and homogeneity did not appear 
to have significant impact on drusen change.
Discussion
In this study, we were able to show that small hard drusen in patients with the CD 
phenotype are subject to a constant dynamic process of drusen remodeling. The initial 
drusen morphology seemed to predict the future course of drusen development. 
Small hard drusen with a decreased reflectivity of overlying RPE or photoreceptor 
layer were more likely to show a regression in drusen volume, whereas pointed small 
hard drusen were more likely to show volume progression.
Although the exact mechanism of drusen biogenesis in CD as well as in “typical” 
AMD is still unclear, an identical mechanism in the developmental courses may 
be expected because of the similar topographic, structural, and compositional 
features.5 In both drusen types, RPE cell pathology seems to play a major role in 
drusen development. Cellular remnants and debris derived from degenerated RPE 
cells become sequestered between the RPE basal lamina and the inner collagenous 
layer of Bruch’s membrane and provoke a chronic inflammatory response 
with complement activation.34–36 Simultaneous with this continuous process of 
accumulating extracellular debris, there is a process of drusen removal that may be 
related to at least 2 factors. 
The first is the removal of these drusen constituents by macrophages.5,10,37 Different 
types of macrophages are present in the normal human choroid.38 In contrast to 
resident choroidal macrophages, Bruch’s membrane macrophages are only seen in 
eyes with drusen, making these macrophages a possible player in the process of 
drusen regression.39 A role for macrophages in the process of drusen removal is 
further supported by animal models that suggest that an impaired mobilization of 
macrophages may prevent the clearance of drusen-like lesions in mice.40,41 
A second mechanism that may explain the removal of drusen could be an altered 
function of protein expression in RPE cells. RPE cells produce and secrete their 
own complement inhibitors, such as complement factor H, complement factor I, 
membrane cofactor protein, vitronectin, and clusterin.11,42–46 The production of 
these complement inhibitors is upregulated in patients with AMD.42 Furthermore, 
vitronectin and membrane cofactor protein are upregulated in the RPE cells that flank 
or overlie drusen.11,42 This production of complement inhibitors by ocular tissues, 
like the RPE cell, plays an important role not only in protecting the eye against 
complement mediated damage but also in maintaining the immuneprivileged state 
of the eye.47 
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Disturbance of the aforementioned factors that induce and sustain chronic local 
inflammation at the level of the RPE–Bruch’s membrane interface, and those that 
attenuate it, can explain the association of a decreased reflectivity of the overlying 
RPE and concomitant photoreceptor layer with drusen regression. A loss of RPE cells 
will result in a decreased generation of extracellular debris that makes up a druse, 
whereas macrophage recruitment and the upregulation of complement inhibitors 
by RPE cells flanking the druse will start a process of druse volume regression. It 
is this process of drusen remodeling that points to a high biochemical activity and 
suggests that future treatments targeting these biochemical processes in an early 
stage of the disease may have a significant role in prophylactic and therapeutic 
interventions in CD.
The finding that drusen progression and drusen regression occurred in all the 
study eyes within a very short period may have implications for clinical studies on 
patients with CD. Because number and size of drusen are important for disease 
staging, longitudinal changes in drusen morphology can be a potential source of 
misclassification and needs attention in epidemiologic studies investigating the 
natural history of CD as well in clinical trials evaluating the efficacy of possible 
therapies. 
Our study has some limitations. First of all, the limited number of eyes restricts the 
general use of our data. However, because drusen remodeling was observed in 
all study eyes, those changes are very likely to occur commonly in eyes with CD. 
Secondly, slight variations of SD-OCT scan positions during follow-up visits cannot 
be excluded. However, eye movements were automatically registered and corrected 
for “eye tracking,” resulting in high repeatability and reproducibility of the SD-
OCT scans; therefore, small shifts of only a few microns could have influenced the 
appearance of these very small drusen in basal laminar drusen.29,32 On the other 
hand, it is unlikely that random shifts may lead to nonrandom, continuous changes 
during the study period. We included only drusen with increasing or decreasing 
drusen volume at all time points (at baseline, after 2 months, and after 4 months) 
for progression analysis to further reduce the possibility for such a systematic 
measurement error.
In summary, we were able to demonstrate that small hard drusen in patients with 
CD show a constant remodeling process. This dynamic process may be a potential 
source of misclassification in disease staging at a single point of time. Changing 
the balance between the generation and the elimination of these drusen in an early 
stage of the disease may be a new target for therapeutic strategies.
short-term chanGes of cuticular drusen
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General discussion
This thesis focuses on the clinical and genetic characteristics of cuticular drusen, 
a subtype of age-related macular degeneration (AMD). We analyzed the genetic 
defects that might cause cuticular drusen, and we evaluated the association of 
possible genetic and/or environmental risk factors with this AMD subtype. In the 
previous chapters of this thesis, the merits and limitations of each study were 
discussed in detail. In this chapter, the primary findings of this thesis are reviewed 
and placed in a broader perspective, and particular emphasis is given to the role 
that genetic research has played in unraveling the etiology of cuticular drusen and 
the implications of our results with respect to clinical practice and future research.
Cuticular drusen and age-related macular degeneration
Cuticular drusen are typically first visible on ophthalmoscopy in early adulthood and 
are often an incidental finding during a routine ophthalmological examination.1-3 
Cuticular drusen are usually small and, although they grow in size over time, they 
rarely exceed 125 µm in diameter.4,5 In the early stages—which are asymptomatic—
cuticular drusen are distributed randomly throughout the fundus. In time, they 
thend to grow in number and become grouped in clusters with similar density in 
both eyes.1-3,6,7 These clusters can be arranged in a tightly knit pattern that gives the 
entire posterior pole an “orange-peel” appearance on ophthalmoscopy. In the later 
stages, cuticular drusen can reach confluence and may eventually damage/affect the 
adjacent RPE and neuroretina, causing localized or patchy chorioretinal atrophy. In 
the macula, these confluent drusen can also lead to serous “pseudovitelliform” RPE 
detachment, which can reduce visual acuity.8,11 An early report suggested a relatively 
benign course with spontaneous resolution of the RPE detachment in approximately 
50% of cases.9 However, more recent studies found no cases of spontaneous 
resolution but instead reported enlarged areas of detached RPE that can become 
atrophic and/or result in the formation of choroidal neovascularization (CNV).2,8,9,12 
In agreement with the relatively early onset of cuticular drusen, the onset of CNV 
in patients with cuticular drusen occurs nearly ten years earlier than in patients with 
other drusen phenotypes in AMD.13,14
The lack of differences between cuticular drusen and other drusen phenotypes in 
AMD with respect to structure, composition and location—as well as the ability of 
cuticular drusen to progress into advanced AMD—suggest that cuticular drusen 
differ from other drusen phenotypes only by their early onset and number. However, 
this is an oversimplification: the characteristic early angiographic features of cuticular 
drusen also distinguish these drusen from other drusen, suggesting that there are 
indeed differences in composition.7 It has been hypothesized that this difference may 
be explained by differences in lipid composition, which could not be measured in 
previous immunohistochemical studies due to the use of xylene, which is necessary 
to extract the paraffin in which the cuticular drusen-affected eyes were embedded.15
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Genetics of cuticular drusen
The unique distribution and fluorographic characteristics of cuticular drusen allow 
clinicians to reliably differentiate between cuticular drusen and other drusen 
phenotypes. Nevertheless, the similarities between the various drusen phenotypes 
with respect to their location between the basal lamina of the RPE and the inner 
collagenous layer of Bruch’s membrane, substructure and composition suggest a 
common developmental pathway. It is therefore not surprising that we (see Chapter 
2) and others have found that the cuticular drusen phenotype shares some of 
the same risk factors as AMD in general, although the degree of the association 
varies.16,17 Whereas most of the previously identified demographic, environmental 
and genetic AMD risk factors confer a similar effect (i.e., odds ratio (OR)) in both 
groups, the effect of smoking and the frequency of the complement factor H (CFH) 
Y402H risk allele differed significantly between the groups. Specifically, smoking had 
a significantly lower association with the cuticular drusen phenotype (OR = 2.06) 
than with AMD in general (OR = 5.97). On the other hand, the CFH Y402H variant 
appeared to be more tightly correlated with the cuticular drusen phenotype—the 
allele frequency of the CFH Y402H variant was 64% in cuticular drusen versus 58% 
in AMD in general and 38% in normal controls.17 Both of these findings suggest that 
one’s genetic constitution has a higher contribution to cuticular drusen than to AMD 
in general and highlight the importance of complement factor H in the development 
of cuticular drusen.
Complement factor H
Complement factor H is one of the principal regulators of the complement system. 
This protein’s primary function is to inhibit the alternative complement pathway 
by competing with factor B binding to C3b, thereby accelerating the decay of the 
alternative pathway C3 convertase and acting as a cofactor in the factor I-mediated 
proteolytic inactivation of C3b.18-20 RPE cells express factor H at a level that is 
comparable to the highest expression levels in the liver, where plasma factor H is 
synthesized.21 In vitro studies have revealed that oxidative stress generally decreases 
factor H expression in the RPE, thereby increasing local complement activity.22,23 
Individuals who are homozygous for the CFH Y402H polymorphism appear to have 
levels of CFH gene transcription and factor H protein levels in their RPE that are 
similar to the levels in individuals who are homozygous for the wildtype allele.24 
However, homozygous CFH Y402H carriers have decreased binding of factor H to 
sulfated glycosaminoglycans (which are found on host tissues) as well as decreased 
binding to other ligands, including C-reactive protein, necrotic cells and bacterial 
coat proteins.25 Among these effects, the change in the glycosaminoglycan-
recognizing property of factor H is likely to be the most relevant to cuticular drusen 
and AMD in general.
The important role played by factor H in the development of cuticular drusen became 
even more evident following the identification of heterozygous loss-of-function 
mutations in the CFH gene among families with the cuticular drusen phenotype. In 
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a study published by Boon et al., a recessive disease model was suggested in which 
patients with cuticular drusen have a CFH mutation on one allele together with the 
CFH Y402H variant on the other allele.1 In Chapter 3 of this thesis, we confirmed 
that a heterozygous CFH gene mutation can cause cuticular drusen in a subgroup 
of patients, although a recessive disease model involving the Y402H allele was not 
apparent in these families. As we described, 5 out of 10 patients carried both the 
CFH mutation on one allele and the Y402H variant on the other allele. However, 
we cannot exclude the possibility that unidentified variants in other genes can 
contribute to the development of cuticular drusen, thereby adding to the burden 
of heterozygous CFH mutations. In addition to the loss-of-function mutations that 
were detected in our study, a recent study reported a rare heterozygous mutation 
(R1210C) in the CFH gene that confers a high risk of developing AMD.26 Because the 
patients in this study had progressed to late AMD, differentiating between “regular” 
AMD and cuticular drusen was not possible. Nevertheless, we speculate that these 
patients had cuticular drusen in the early stages of their disease. Indeed, our recent 
finding of the R1210C mutation in two unrelated patients with cuticular drusen 
(unpublished data) supports this hypothesis.
In addition to cuticular drusen, mutations in the CFH gene have also been associated 
with the renal diseases membranoproliferative glomerulonephritis (MPGN) type 
II and atypical hemolytic uremic syndrome (aHUS). Nearly 80% of MPGN type II 
patients have cuticular drusen and these are considered pathognomonic for this 
renal disorder.27 Histopathologically, the deposits in MPGN type II and AMD/
cuticular drusen are similar in a number of aspects. In both diseases, the deposits 
have comparable saccharide compositions and contain cholesterol, amyloid P 
component, vitronectin and a wide variety of complement components.28-30 In view 
of the fundoscopical and histopathological similarities between MPGN type II and 
AMD-related cuticular drusen—as well as the association of both diseases with CFH 
gene mutations—one might expect a high rate of MPGN type II in patients affected 
by AMD. However, a high rate of co-morbidity has not yet been described in large 
epidemiological studies.31 Within the relatively small cohort of patients that we 
described in Chapter 3, two patients (patient B-II:1 and patient C-II:4) with cuticular 
drusen caused by a heterozygous mutation in their CFH gene also had MPGN type 
II.3 However, family members who had the same mutation showed no signs of renal 
failure based on their blood test results. This suggests that an additional factor (for 
example, a second mutation or an external trigger) is needed to develop MPGN 
type II. Indeed, several patients with MPGN type II have been reported to carry 
homozygous or compound heterozygous mutations in CFH.32-35 Interestingly, we 
recently saw a patient in our clinic with cuticular drusen who had developed MPGN 
type II following a streptococcal infection (unpublished data). 
With respect to patients with aHUS, no drusen or other AMD-like changes have 
been described to date. This is remarkable, given that the genetic link between 
AMD/cuticular drusen and aHUS is even stronger than the link with MPGN type II, 
and both disorders have been associated with the heterozygote R1210C mutation in 
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the CFH gene.26,36-38 In aHUS, most R1210C mutation carriers are also heterozygous 
for mutations in other complement genes or tend to have more risk factors for 
developing aHUS.37 Therefore, the pathogenicity of a heterozygous CFH mutation 
alone is insufficient to develop aHUS, just as it is insufficient to develop MPGN 
type II. This additive model of multiple factors could explain why AMD/cuticular 
drusen patients who carry the R1210C mutation fail to develop aHUS. Patients with 
aHUS generally have a mutation on the other allele or in other complement genes. 
However, why no patients with the R1210C mutation and who have aHUS have been 
reported to have AMD/cuticular drusen remains a mystery.
Complement factor I
Complement factor I is a serine protease that circulates in an inactive form and 
can inactivate all complement pathways by cleaving the α’-chain of the activated 
complement factors C3b and C4b.39,40 The presence of specific cofactors such as factor 
H, membrane co-factor protein, complement receptor 1 and C4b-binding protein is 
required for enhancing this cleavage.19,41-43 Like factor H, factor I is also required 
both to maintain complement homeostasis in plasma and to restrict complement 
activation. The importance of the regulatory role of factor I is highlighted by the 
fact that rare CFI mutations can predispose individuals to develop diseases such as 
aHUS and systemic lupus erythematosus.44,45 
In light of the functional similarities between factor I and factor H, it was no surprise 
that the CFI gene was recently identified as a second gene to harbor mutations in 
patients with cuticular drusen. As described in Chapter 4, two specific CFI gene 
mutations (G119R and G188A) confer a high risk of developing AMD. Most (n = 
13) of the patients who carry a CFI mutation and for whom fundus photographs 
were available (n = 14) exhibited the cuticular drusen subtype of AMD (unpublished 
results). The G119R mutation has also been linked to aHUS,44,46 hinting again at 
a genetic association between cuticular drusen and aHUS. However, none of the 
patients in our cohort who had cuticular drusen and the G119R mutation had 
clinically significant renal dysfunction. As noted above, to develop aHUS, a single 
G119R mutation must be accompanied by a second mutation either on the other 
CFI allele or in another complement gene.44,46 Once again, a key question remains: 
why have patients with aHUS who carry the G119R mutation never been reported 
to develop cuticular drusen? This lack of patients with cuticular drusen may simply 
be due to a lack of observational reports; therefore, we strongly recommend that 
clinicians perform an ophthalmic examination in patients who have aHUS caused by 
a mutation in either their CFH or CFI gene.
Identifying new mutations in cuticular drusen
In Chapters 3 and 4, we demonstrated that in addition to polymorphisms (Chapter 
2), CFH and CFI gene mutations can also contribute to the development of cuticular 
drusen. Indeed, theoretical modeling favors a scenario in which a significant portion 
of the genetic risk for developing common diseases such as AMD is due to mildly 
deleterious mutations that are maintained at a low frequency in the population by 
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weak purifying selection.47 Because several common variants in genes encoding 
components of the complement system are strongly associated with both AMD and 
the AMD subgroup cuticular drusen, selecting and prioritizing these genes in the 
search for additional disease-causing mutations seems to be the most logical next 
step. However, we cannot exclude the possibility that genes that have not yet been 
associated with AMD may contain mutations that can cause cuticular drusen. The 
use of new genetic techniques such as exome sequencing will definitely facilitate the 
identification of such mutations.
Clinical implications and future perspectives
At least two clinically relevant aspects can be drawn from the findings that are 
reported in this thesis. The first is genetic counseling, which became possible after 
the identification of the disease-causing genetic defect in a fraction of patients with 
cuticular drusen. By recognizing the genetic cause of the disease, the clinician can 
then inform the affected families more accurately regarding the prognosis, which 
can include an increased risk for developing cuticular drusen and cuticular drusen-
related AMD. Furthermore, knowing the genetic defect may improve diagnostic 
accuracy and raise awareness of any disease-related co-morbidity that may develop 
in patients or their family members as a result of the same genetic defect. As shown 
in Chapter 3, patients with cuticular drusen who carry a mutation in the CFH gene 
have a higher risk for developing MPGN type II. Screening these patients (in a 
preclinical stage) for MPGN type II will enable the clinician to initiate treatment in a 
much earlier stage, which may ultimately prevent end-stage renal failure.48  
As an integrative component of their genetic counseling, patients with cuticular 
drusen—and particularly their family members—should be made aware of the tests 
that are currently available for predicting AMD (e.g., ArcticDx, Sequenom). These 
tests are based on a small number of common variants and are therefore not reliable 
for individuals who carry a disease-causing mutation. Understanding the role of 
rare variants in AMD is therefore necessary before reliable genetic tests can be 
developed. Conversely, the relationship between genetic variants and AMD subtypes 
(for example, geographic atrophy and neovascular AMD, as well as cuticular drusen) 
must be understood better. To provide patients with timely and effective treatment 
options, reliable prognostic tests are needed to determine who is at high risk for 
developing AMD. These tests should be based on a small number of common 
variants but should also address rare, highly penetrant variants, particularly for the 
cuticular drusen phenotype, which is caused by rare mutations in a proportion (~8%) 
of cases (unpublished data). 
The second clinically relevant aspect of our findings is that patient care will 
improve with a better understanding of the etiology of cuticular drusen. This thesis 
supports the notion that considering the entire population of AMD patients as 
homogeneous is an oversimplification. Cuticular drusen is only one distinct AMD 
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subgroup and has an etiology that differs from other AMD subtypes, and this 
difference has consequences with respect to prevention and future treatments. 
Because complement abnormalities are more prevalent in patients with the cuticular 
drusen phenotype, therapies that target specific components of the complement 
system are—at least in theory—more promising for treating this AMD subgroup. 
It is important to differentiate this class of therapies from anti-VEGF-A agents 
(which are the current conventional treatment for end-stage neovascular disease), 
as complement-based therapeutics can intervene earlier in the disease process, 
perhaps preventing atrophic lesions and promoting recovery from cuticular drusen. 
The latter effect is supported by our findings in Chapter 5, which show that cuticular 
drusen can regress without anatomical damage. The therapeutic agents for treating 
AMD that are currently in either clinical trials or late-stage preclinical evaluation are 
listed in Table 6.1. To select the most suitable treatment, the drug’s mechanism of 
action and its route/site of administration should be taken into consideration. 
Based on their mechanism of action, the therapeutic agents that are currently 
under investigation can be divided into the following four classes: 1) monoclonal 
antibodies, 2) complement component inhibitors, 3) receptor antagonists, and 4) 
supplementation therapy. Monoclonal antibodies and complement component 
inhibitors suppress complement activation by binding to specific target cells 
and by preventing the formation of key elements within the proteolytic cascade, 
respectively. Each of these actions in turn prevents downstream complement 
activation and the formation of the membrane attack complex. It is important to note 
that most of these inhibitors target common complement pathway components and 
can therefore cause serious side-effects due to their concomitant inhibition of all 
three major complement pathways. This potential consequence can be avoided by 
selecting more specific agents such as receptor antagonists (e.g., the C5a receptor 
antagonist).49 Unlike C5a inhibitors, receptor antagonists competitively bind to the 
C5a receptor, thereby neutralizing its normal interactions. Receptor antagonists can 
therefore selectively suppress the inflammatory response without adversely affecting 
the entire complement-related immune system.50 The last class of therapeutics that 
is currently under investigation is the supplementation therapy group. Recombinant 
factor H is currently under preclinical development and may serve as a promising 
treatment option for patients with early stage cuticular drusen caused by a loss-of-
function mutation in the CFH gene. In theory, this augmentation therapy should help 
restore homeostatic regulation of the alternative complement pathway.
To achieve the best results possible, clinicians must select the optimum route of 
administration for their drug of choice. The CFH Y402H variant that is associated 
with a high risk of developing AMD was recently found to protect against systemic 
inflammatory response syndrome in children.51 The R32Q variant of complement 
factor B,52 which decreases the risk of developing AMD, increases the susceptibility 
to develop cardiomyopathy in patients with Chagas disease.53 The above examples 
demonstrate that local delivery may be favored over systemic administration in order 
to avoid undesired systemic effects.
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In conclusion, the findings reported in this thesis demonstrate that genetic factors 
play a larger role in patients with cuticular drusen AMD than in other AMD types. 
These findings may explain why, compared to AMD in general, cuticular drusen 
develop at a younger age and are more often clustered within families. Identifying 
the genetic defects that underlie the development of cuticular drusen will improve 
our understanding of this AMD subtype and will help clinicians customize the 
treatment to match the patient. To date, we have identified two genes that harbor 
rare, highly penetrant variants that can cause cuticular drusen. Determining which of 
the approximately 25,000 genes in the human genome harbor genetic defects that 
can contribute to the development of cuticular drusen will be a challenging task in 
the coming years.
General discussion
Drug (Trade name) Current stage of development
Soliris (Eculizumab) Phase II (ongoing, no longer recruiting)
C1-INH Preclinical
JPE-1375/JSM-7717 Preclinical
Recombinant CFH Preclinical
1 - Monoclonal antibody that targets
     complement  factor D
1 - Monoclonal antibody that targets
     complement factor B
2 - C3 inhibitor – prevents cleavage of 
     C3 into C3a and C3b
2 - C5 inhibitor – prevents cleavage of 
     C5 into C5a   and C5b
2 - Protease inhibitor
3 - C5a receptor antagonist
4 - CFH supplementation
Abbrevations: CFH, complement factor H
POT-4 (Compstatin) Phase I (completed)
ARC1905 Phase I (ongoing, no longer recruiting)
TA106 Preclinical
Anti-factor D (FCFD4514s) Phase II (ongoing, no longer recruiting)
Table 6.1. Summary of anti-complement therapies for age-related macular degeneration
Class and mechanism of action
1 - Monoclonal antibody targeting C5
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Summary
Age-related macular degeneration (AMD) is a degenerative disease of the central 
retina and the most common cause of irreversible and progressive visual loss 
among the elderly in the Western world. AMD is a heterogeneous disorder, with 
several clinically recognized subtypes like the cuticular drusen phenotype. Despite 
intensive research on AMD in the last two decades, most of the AMD subtypes 
remain scarcely investigated. The aim of this thesis was to add to the insights in the 
clinical characteristics and genetic causes of cuticular drusen, and subsequently to 
contribute to a better understanding of this AMD subtype. This may enable better 
counseling of patients and their families, as well as tailor the choice of the therapeutic 
approach to this specific AMD subtype.  
Chapter 1 provides a general introduction to the processes that lead to vision, the 
retinal anatomy, the imaging techniques used to evaluate retinal anatomy, molecular 
genetics, and describes the clinical and pathological aspects of AMD. 
In Chapter 2, we investigated whether the association of cuticular drusen with several 
AMD risk factors is different from that of AMD as a whole. To perform this analysis, 
all major environmental and genetic risk factors previously found to be associated 
with AMD were evaluated in a cohort of 217 patients with cuticular drusen, a cohort 
of 540 patients with AMD who did not display cuticular drusen, and a cohort of 553 
age-matched controls. We found that cuticular drusen was associated with most 
previously identified AMD risk factors. However, the association with the CFH Y402H 
risk allele appeared to be stronger, whereas the association with smoking was less 
pronounced when compared to AMD as a whole. These findings suggest a more 
important role for genetic factors than environmental factors in the developmental 
course of cuticular drusen. 
Chapter 3 describes a detailed clinical and molecular genetic analysis of 11 patients 
with cuticular drusen from 3 different families, who all carried a novel heterozygous 
mutation in the CFH gene. A broad phenotypic variation was observed, ranging 
from limited macular drusen to extensive drusen in the posterior pole as well 
as the peripheral retina, even in association with a single CFH mutation. Two 
patients developed end-stage kidney disease as a result of membranoproliferative 
glomerulonephritis type II, a second disease that can be caused by a mutation in 
the CFH gene. These findings suggest that patients with extensive cuticular drusen 
caused by a CFH gene mutation should undergo screening for renal function to 
preclude preclinical membranoproliferative glomerulonephritis type II.
Chapter 4 presents the identification of a rare, highly penetrant missense mutation, 
G119R, that confers a high risk of AMD in the CFI gene, an AMD candidate by virtue of 
association of non-coding variants near the locus. We found that plasma of patients 
carrying the G119R mutation mediated the degradation of C3b at a significantly lower 
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level compared to patients without a mutation in CFI. Recombinant protein studies 
revealed that the G119R mutant is both expressed and secreted at significantly 
lower levels than wild type protein. Consistent with these findings, 119R-encoding 
human mRNA had reduced activity compared to 119G in regulating vessel thickness 
and branching in the zebrafish retina. Taken together, these findings indicate an 
obligate role for CFI in the pathogenesis of AMD and demonstrate that rare, highly 
penetrant mutations contribute to the genetic variance of AMD, with implications 
for predictive testing and personalized treatment.
In Chapter 5, we asked ourselves whether drusen in patients with cuticular drusen 
show short-term morphological changes. This question is interesting because the 
size and number of drusen are used for disease staging and for the prediction of the 
likelihood of disease progression and vision loss. In order to answer this question, 
ten subjects with cuticular drusen were longitudinally followed during a period of 
4 months by spectral-domain OCT. Interestingly, all eyes showed drusen with a 
spontaneous change in volume. Subsequently, we investigated whether morphologic 
parameters may be predictive for processes of progression or regression of drusen. 
We found that pointed drusen  showed a significant association with a progression in 
volume, while drusen with overlying photoreceptor layer or RPE damage showed a 
significant association with a regression in volume. These findings reveal a potential 
source of misclassification in disease staging. In addition, the dynamic nature of 
cuticular drusen points to high biochemical activity that may be sensitive to future 
pharmacologic treatment strategies.
 
In Chapter 6, the findings of the work described in this thesis are discussed and 
implications for scientists, ophthalmologists and patients are presented. After a 
brief introduction on the history of cuticular drusen, the role of rare mutations in the 
development of this AMD subtype is presented. Finally, the clinical implications of 
the genetic findings are discussed, like the possibility of genetic counseling and how 
a better understanding of the etiology of cuticular drusen will help us to tailor our 
choice of treatment.
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Samenvatting
Leeftijdsgebonden maculadegeneratie (LMD) is een degeneratieve aandoening van 
de centrale retina en de meest voorkomende oorzaak van irreversibel en progressief 
visusverlies onder ouderen in de Westerse wereld. LMD is een heterogeen ziektebeeld 
met verschillende klinische subtypes, waaronder cuticular drusen. Ondanks intensief 
onderzoek naar LMD de afgelopen twintig jaar is er maar weinig bekend over de 
verschillende subtypes van LMD. Het doel van dit proefschrift was om meer inzicht 
te verwerven in de klinische kenmerken en de genetische oorzaken van cuticular 
drusen om zo bij te dragen tot meer kennis over dit subtype van LMD. Dit zou 
kunnen bijdragen aan een betere voorlichting voor patiënten en hun familieleden, 
alsook een meer toegespitste therapeutische aanpak van dit specifieke subtype van 
LMD.
Hoofdstuk 1 geeft een algemene introductie in het proces waardoor ons zicht tot 
stand komt, de anatomie van de retina, de technieken welke gebruikt worden om 
de retinale anatomie in beeld te brengen, de moleculaire genetica en beschrijft de 
klinische en pathologische aspecten van LMD.
In Hoofdstuk 2 hebben we onderzocht of de associatie tussen cuticular drusen en de 
verschillende risicofactoren van LMD anders is dan bij LMD in het algemeen. Om dit 
te onderzoeken hebben we alle belangrijke omgevings- en genetische risicofactoren 
die geassocieerd zijn met LMD geëvalueerd in een cohort van 217 patiënten met 
cuticular drusen, een cohort van 540 patiënten met LMD zonder het cuticular drusen 
subtype en in een cohort van leeftijdsgematchte controle personen. We vonden 
dat het cuticular drusen fenotype geassocieerd is met de meeste risicofactoren die 
ook geassocieerd zijn met LMD in het algemeen. Echter, de associatie met het CFH 
Y402H risico allel bleek sterker, terwijl de associatie met roken minder uitgesproken 
bleek te zijn dan met LMD in het algemeen. Deze bevindingen suggereren dat 
genetische factoren een belangrijkere rol spelen in de ontwikkeling van cuticular 
drusen dan omgevingsfactoren.
Hoofdstuk 3 beschrijft een gedetailleerde klinische en genetische analyse van 11 
patiënten met cuticular drusen uit 3 verschillende families die allen drager zijn van 
een nieuwe heterozygote mutatie in het CFH gen. Er werd een brede variatie gezien 
in de klinische presentatie, variërend van enkele drusen in de macula tot een grote 
hoeveelheid drusen verspreid over de hele retina. Deze variabele presentatie werd 
zelfs gezien in patiënten die dezelfde mutatie droegen. Twee patiënten ontwikkelden 
membranoproliferatieve glomerulonefritis type II, een aandoening die eveneens 
veroorzaakt kan worden door een mutatie in het CFH gen. Deze bevindingen 
suggereren dat een nierfunctiescreening bij patiënten met cuticular drusen nuttig 
kan zijn om membranoproliferatieve glomerulonefritis type II al in een preklinisch 
stadium te kunnen uitsluiten.
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Hoofdstuk 4 beschrijft de ontdekking van een zeldzame, hoogpenetrante missense 
mutatie (G119R) in het CFI gen. In het plasma van patiënten met de G119R mutatie 
was een significant lagere afbraak van C3b in vergelijking met patiënten zonder 
mutatie te zien. Vervolg studies lieten zien dat het gemuteerde G119R eiwit lager 
tot expressie komt en minder uitgescheiden wordt dan het wildtype eiwit. In lijn met 
deze bevindingen had het 119R coderende humane mRNA een verlaagde activiteit 
in vergelijking met 119G in de regulering van vaatdikte en vaatvertakking in de retina 
van zebravissen. Concluderend laten deze bevindingen zien dat CFI een belangrijke 
rol speelt in de pathogenese van LMD en dat zeldzame hoogpenetrante missense 
mutaties bijdragen aan de genetische variatie van LMD. Bovendien heeft dit de 
nodige implicaties heeft voor voorspellende testen voor LMD en behandeling op 
het niveau van de individuele patiënt. 
In Hoofdstuk 5 vroegen we onszelf af of de drusen in patiënten met cuticular drusen 
morfologische veranderingen op korte termijn lieten zien. Deze vraag is interessant 
omdat de grootte en het aantal drusen wordt gebruikt om de ernst van het ziektebeeld 
te bepalen en de prognose van ziekteprogressie en visusverlies in te schatten. Om 
deze vraag te kunnen beantwoorden hebben we 10 patiënten met cuticular drusen 
gedurende een periode van 4 maanden gevolgd met spectral-domain OCT. Het 
opmerkelijke was dat alle ogen een spontane verandering in drusenvolume lieten 
zien. Vervolgens hebben we onderzocht welke morfologische parameters een 
voorspellende waarde hadden voor drusenprogressie of drusenregressie. Hierbij 
vonden we dat puntvormige drusen een significante associatie lieten zien met 
progressie van drusenvolume, terwijl drusen met overliggende fototoreceptorschade 
of RPE schade een significante associatie met regressie van drusenvolume lieten 
zien. Deze bevindingen laten een potentiële bron van misclassificatie van het 
ziektestadium zien. Tevens wijst de dynamiek van drusen op een hoge biochemische 
activiteit wat aangrijpingspunten kan bieden voor toekomstige farmacologische 
interventies.
In Hoofdstuk 6 worden de bevindingen uit dit proefschrift en de implicaties daarvan 
voor wetenschappers en klinici bediscussieerd. Na een korte inleiding over de 
geschiedenis van cuticular drusen, wordt de rol van zeldzame mutaties beschreven 
in de ontwikkeling van dit subtype van LMD. Tot sluit worden de klinische implicaties 
van de gevonden bevindingen besproken, zoals de mogelijkheid van genetische 
voorlichting en hoe een beter begrip van de etiologie van cuticular drusen kan 
helpen in de keuze voor therapie.
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Dankwoord
Bijna aangekomen bij het eind van mijn proefschrift, biedt er zich een mooie 
gelegenheid aan om even stil te staan en terug te blikken op een mooie en 
bijzondere periode uit mijn leven. Door de buitenstaander wordt promoveren vaak 
geassocieerd met het doen van onderzoek, het opschrijven van je resultaten in de 
vorm van een artikel en dit vervolgens te publiceren. Wie promoveren op deze 
manier definieert is waarschijnlijk zelf nooit gepromoveerd. Promoveren is namelijk 
veel meer! Het is tevens een ontdekkingsreis van jezelf, waarbij je prestaties leert 
neerzetten die je voorheen voor onmogelijk achtte, maar waarbij je ook zeker je 
beperkingen leert kennen. Er wordt een beroep gedaan op je creativiteit, flexibiliteit 
en je incasseringsvermogen wordt tot het uiterste getest. Gedurende dit proces 
word je bijgestaan door een heel team die je vanaf de zijlijn voorziet van goed 
advies. Promoveren doe je dan ook niet alleen, ondanks dat de enkele naam op de 
voorkant van dit proefschrift wellicht anders doet vermoeden. Ik realiseer me dat 
het onmogelijk is om eenieder te bedanken die een bijdrage heeft geleverd aan dit 
proefschrift. Toch wil ik een aantal mensen hier in het bijzonder noemen vanwege 
hun belangrijke bijdrage.
Mijn grootste dank ben ik verschuldigd aan alle patiënten en proefpersonen die 
deel hebben genomen aan mijn onderzoek. Zonder u was dit proefschrift simpelweg 
nooit tot stand gekomen. Met diepe respect heb ik mogen ervaren hoe u bereid was 
van heinde en verre naar Nijmegen af te reizen om de vaak lange onderzoekssessies 
te ondergaan. Ofschoon uw bijdrage formeel in anonimiteit plaatsvindt, vormt uw 
deelname een belangrijke bijdrage voor de toekomstige ontwikkelingen binnen de 
oogheelkunde. Dank daarvoor.
Prof. dr. C.B. Hoyng, beste Carel, ik heb je mogen ervaren als een man vol humor en 
relativeringsvermogen. Je gaf me veel vrijheid in het doen van onderzoek, maar wist 
me altijd weer een duw in de goede richting te geven als ik het grotere geheel uit 
het oog dreigde te verliezen. Jouw kracht schuilt in het herkennen van potentieel in 
alles en iedereen. Ik wil je dan ook graag bedanken dat je in mij geloofde en de kans 
die je me hebt geboden als onderzoeker.
Prof. dr. J.E.E. Keunen, bij u heb ik de stap naar het tutoyeren nooit durven te maken, 
terwijl u juist een van de meest toegankelijke personen bent die ik ken. Ik wil ook u 
bedanken voor de vrijheid die u me bood in het doen van onderzoek en voor kans 
om me te bewijzen als onderzoeker.
Dr. A.I. den Hollander, beste Anneke, toen ik mijn eerste stapjes waagde op het 
gladde ijs van de genetica bleek jij een uiterst geschikte schaatslerares te zijn. Ik 
heb je leren kennen als een geduldig, begripvol en begaafd moleculair geneticus. 
De snelheid en correctheid waarmee jij mijn artikelen nakeek heeft respect 
afgedwongen.
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Dr. B.J. Klevering, beste Jeroen, niemand kan een boodschap overbrengen zoals 
jij dat kan. Met dit vermogen was jij dan ook vaak degene die de puntjes nog flink 
aan wist te scherpen alvorens de artikelen de deur uitgingen. Ik hoop ook in de 
toekomst nog veel van je te kunnen leren.
Dr. T. Theelen, beste Thomas, met jouw enthousiasme voor en kennis van de 
verschillende vormen van “imaging” wist je mij te overtuigen dat er meer was dan 
genetica. Het resultaat hiervan zien we terug in hoofdstuk 5 van dit proefschrift.
Dr. C.J.F. Boon, beste Camiel, jouw pionierswerk op het gebied van cuticular drusen 
in Nijmegen heeft mede geleid tot dit proefschrift. Jij was dan ook de ideale 
sparringpartner als ik weer eens een nieuwe hypothese had over cuticular drusen. 
Daarnaast ben je ook gewoon een toffe peer met wie ik veel heb kunnen lachen 
tijdens onze wetenschappelijke uitjes.
Vervolgens een speciale plek voor mijn (oud) mede-promovendi van de afdeling 
oogheelkunde. Waar we ooit met twee promovendi waren bleef het team elk jaar 
exponentieel groeien. Dženita, Mahesh, Ramon, Yara, Shazia, Nicole, Freekje, 
Constantin, Michel en Myrte, door jullie aanwezigheid was onderzoek doen naast 
de serieuze momenten ook gewoon leuk! Ik hoop de meesten van jullie straks ook 
weer als collega’s te mogen verwelkomen in het assistententeam.
Frederieke en Bjorn, ook zonder jullie had dit proefschrift er nooit kunnen komen. 
Jullie waren altijd bereid om de genetische analyses uit te voeren als ik weer een 
interessante mutatie op het spoor was.
Bert en Tiny, jullie waren altijd druk in de weer met het verwerken en ordenen van 
alle bloedmonsters die er werden verzameld door de promovendi.
Het hele optometristenteam, speciaal Hans en Jack, wil ik bedanken voor de 
honderden foto’s die jullie hebben gemaakt van de patiënten en proefpersonen. 
Altijd kon ik bij jullie terecht voor het maken van nog een set aan extra foto’s, terwijl 
het eigenlijk niet uitkwam. Dank hiervoor.
Hans Groenewoud dank ik voor zijn grondige en snelle statistische analyses als ik 
er zelf niet uitkwam. De dames van het Trialcentrum voor de ondersteuning die 
ze boden tijdens de AMD-dagen bij het verzamelen van patiënten. De dames en 
enkele heer van de administratie als ik weer eens langskwam om een patiënt in te 
boeken. De dames van de verpleegpost voor de nodige ondersteuning tijdens de 
onderzoeken.
Mijn (studie)vrienden, Hilbert, Jacob, Guus, Bob, Bert-Jan, Stan, Pieter en Babak, 
dank voor jullie belangstelling, steun en broodnodige afleiding ondanks jullie eigen 
drukke agenda’s. Vriendschap is geen illusie.
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Ook mijn ouders Jo en Francien van de Ven wil ik graag apart noemen. Lieve ouders, 
jullie hebben mijn hele leven al achter me gestaan en met raad en daad ondersteund 
in alle beslissingen die ik nam. Ik begon aan mijn promotie in een moeilijke periode 
voor ons gezin. We dachten deze periode afgesloten te hebben, maar kregen vrij 
recent te horen dat pa ongeneeslijk ziek is. Ik houd ontzettend veel van jullie en 
waardeer jullie enorm. Ik weet dat ik dat door alle drukte weleens vergeet te zeggen, 
daarom schrijf ik het hier nu voor eens en altijd op. En pa, dit proefschrift draag ik 
op aan jou.
Zo ook dank aan mijn zussen Wendy en Esther. Ik kon altijd bij jullie terecht. Ook 
wanneer ik steeds minder mijn gezicht liet zien. Ik hoop dat ik nu na de afronding 
van mijn proefschrift mijn gezicht vaker bij jullie om de hoek mag steken. Wellicht 
dat Timo en Tara hun oom dan niet meer als onbekende zien. 
Lieve Kamila, op jou kon ik altijd rekenen als mijn rots in de branding. Jij wist me op 
de juiste momenten te motiveren en op andere momenten juist weer te relativeren. 
De laatste loodjes van dit proefschrift waren voor jou minstens zo zwaar als voor mij, 
maar gelukkig kunnen we nu samen genieten van het resultaat. Kocham çie!
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